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Abstract 
 
TBP-1/Tat-Binding Protein 1 (also named Rpt-5, S6a or PSMC3) is a 
multifunctional protein, originally identified as a regulator of HIV-1-Tat 
mediated transcription.  
It is an AAA-ATPase component of the 19S regulative subunit of the 
proteasome and, as other members of this protein family, fulfils different 
cellular functions including proteolysis and transcriptional regulation. 
Consistent with the role in protein destruction, TBP-1 has been shown to 
enhance the ubiquitin ligase function of the VHL (Von-Hippel-Landau) tumour 
suppressor toward Hif1? and to be involved in the degradation of Fra-1 (Fos 
related antigen -1), both overexpressed in a variety of human cancers. 
Moreover, TBP-1 binds to and stabilizes the p14ARF human oncosuppressor, 
likely avoiding its entrance into the proteasome and increasing its anti-
oncogenic functions.  
Intriguingly, TBP-1 overexpression can inhibit cell proliferation in a different 
celllular contexts suggesting that it may function as a negative regulator of cell 
proliferation. Infact, inhibition of the oncogenic phenotype of erb-B 
transformed cells was accompanied by an increase of TBP-1 intracellular levels 
and, accordingly, its overexpression in erb-B transformed cells strongly 
inhibited tumour formation in athymic mice.  
The results presented here demonstrate that stable reduction of TBP-1 
intracellular levels increases cell proliferation, renders cells able to grow also 
in absence of serum, and increases resistance to serum-deprivation induced 
apoptosis of primary human fibroblasts immortalized by h-TERT expression. 
Moreover, TBP-1 silencing determines the activation of the Akt/PKB serin-
threonin kinase, one of the major transducers of growth signals mediating 
proliferative and pro-survival effects. TBP-1 itself turned out to be a 
downstream target of Akt/PKB and MDM2, a known Akt target, plays a major 
role in this regulation. Altogether, these results suggest the existence of a 
negative feedback loop involving Akt/PKB that might act as a sensor to 
modulate TBP-1 levels in proliferating cells. 
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1. BACKGROUND 
1.1  TBP-1, A MULTIFUNCTIONAL PROTEIN COMPONENT OF THE 
19S REGULATORY SUBUNIT OF THE PROTEASOME 26S.  
 
TBP-1/Tat Binding Protein-1 (also named Rpt-5, S6a or PSMC3) is a 
multifunctional protein, originally identified as a regulator of HIV-1-Tat 
mediated transcription (Nelbock et al. 1990).  
The gene coding for TBP-1/PSMC3 mapped to human chromosome 11, in the 
11p12-p13 region (Hoyle et al. 1997). It is ubiquitously expressed in a variety 
of human cell lines and in rodent tissues (Nelbock et al. 1990; Nakamura et al. 
1998). Deletions of this region are present in many types of tumors (Bepler et 
al. 1994; Hoyle et al. 1997).  
Mouse embryo knock out for the PSMC3 gene die before implantation and 
display defective blastocyst development suggesting the importance of the 
TBP-1 protein in the early phases of the embryogenesis and more in general for 
cellular survival (Sakao et al. 2000).  
TBP-1 is a member of a large highly conserved gene family of six AAA 
ATPases (ATPAses Associated to a variety of cellular Activities) and contains 
two conserved domains, one resembling a nucleotide-binding motif (ATP-
binding site), the other resembling a motif common to proteins with helicase 
activity.  
TBP-1, as other five members of the family (MSS1/Rpt-1, S4/Rpt-2, TBP-
7/Rpt-3, SUG2/Rpt-4, SUG1/Rpt-6), is associated with the 19S regulatory 
subunit of the 26S proteasome (Schnall R. et al. 1994) (Figure 1).  
As component of the 19S base of the proteasome, TBP-1, as well as other 19S 
proteins, is involved in the recognition of substrates that have to be degraded, 
their unfolding and subsequent translocation into the 20S proteolytic core.  
In fact, it has been demonstated that 19S proteasome subunits (six AAA 
ATPases) possess chaperone-like activities residing in the ATPase module 
(Braun et al. 1999). 
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Figure 1 Structure of TBP-1.  
 
TBP-1 belongs to the AAA-ATPases gene family and, as well as other members of 
this family, is part of the 19S subunit of the proteasome. 
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1.1.1 The 26S proteasome complex. 
 
The 26S protesome is the chief site of regulatory protein turnover in eukaryotic 
cells. It is a multisubunit complex responsible for the non-lysosomal protein 
degradation in both the nucleus and cytosol (Pickart and Cohen 2004).  
The 26S proteasome is composed of a 20S catalytic core and a 19S regulatory 
subunit that sits as a "collar" on one or both ends of the 20S proteasome 
(Hershko et al. 1998).  
The 20S core complex, which is highly conserved from archea to higher 
eukaryotes, is composed of at least 14 subunits. On the basis of sequence 
similarities, these subunits can be divided into Į and ȕ subfamilies, which 
assemble into four stacked hepatameric rings in ĮȕȕĮ order (Lowe et al. 1995; 
Groll et al. 1997).  
The 19S regulatory particle (RPs) is composed of at least 18 different subunits, 
which are assembled into two main subcomplexes: a ³EDVH´ WKDWFRQWDLQV VL[
ATPase (AAA-ATPases: TBP-1/Rpt-5, MSS1/Rpt-1, S4/Rpt-2, TBP-7/Rpt-3, 
SUG2/Rpt-4, SUG1/Rpt-6) and two non-$73DVH DQG D ³OLG´ FRQWDLQLQJ DW
least 10 non-ATPase subunits that sit on top of the base (Voges et al. 1999).  
The regulatory complex carries out a number of biochemical functions 
including recognition of the polyubiquitinated substrates (Verna et al., 2004), 
its unfolding and translocation into the cavity of the 20S proteasome (Pickart 
and Cohen 2004). Ubiquitinated proteins are sent to the 20S catalytic barrel-
shaped proteasome core by ubiquitin dependent binding to the 19S particles 
whose function is to open the barrel and allow protein entry.  
On the other hand, non-ubiquitinated proteins can also be degraded by the 20S 
proteasome, as well as by the 26S proteasome itself (Kalejta et al. 2003; Asher 
et al. 2005).  
In addition to binding to the 19S regulatory complex, the 20S core can be 
capped by two other activator protein complexes, the 11S (also called PA28 or 
REG) (Hoffman et al. 1992) and PA200 (Ustrell et al. 2002).  
Different from the 26S proteasome, the resulting activated proteasome 
complexes do not recognize ubiquitinated protein substrates, and their activities 
and assembly are ATP-independent.  
There are three 11S homologues, REG Į, ȕ and Ȗ. The REG Į and ȕ subunits 
form a heteroheptameric complex that activate the 20S proteasome and are 
mainly cytoplasmic. This complex can be induced by Ȗ-interferon treatment 
suggesting that REGĮȕ is involved in the MHC class I antigen presentation 
(Slaughter et al. 1992; Realini et al. 1997). The REGȖ subunit forms 
homoheptameric activator complex and is localized in the nucleus.  
The function of this complex is still largely elusive although knock out mice 
suggest a role in the regulation of mitosis and apoptosis (Barton et al. 2004; 
Zannini et al. 2008).  
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The PA200 proteasome activator is a broadly expressed nuclear protein. 
Although how PA200 normally functions is not fully understood, it has been 
suggested to be involved in the repair of DNA double-strand breaks (DSBs) 
(Ustrell et al. 2002). It has been recently isolated a chimerical form of the 
proteasome composed by both the regulative subunits, whose function is not 
yet known (Figure 2). 
 
 
Figure 2 Structure of the proteasome. 
 
The 20S catalytic proteasome can associate with one or two 19S regulative subunit 
giving rise to the 26 proteasome, mainly involved in the degradation of ubiquitinated 
proteins or with the 11S/REG subunit. 
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1.1.2 The 19S regulatory subunits have roles other than proteolysis. 
 
There are different evidences suggesting the involvement of 19S subunit 
protein members in cellular events that do not require proteolysis.  
These proteins play a key role in transcriptional regulation, acting at different 
levels: co-activators recruitment, mRNA elongation, initiation of transcription. 
The first evidences were obtained in yeast, where, by chromatin 
immunoprecipitation assay, it was demonstrated the association between the 
Sug1 and Sug2 proteins with the promoters of the Gal1/10 genes upon 
induction with galactose (Gonzalez et al. 2002).  
The involvement of the 19S subunits in mRNA elongation was reported by 
Ferdous and co-workers (2002). They demonstrated that antibodies against 
Rpt6, the mammalian analogue of Sug1 in yeast can abolish activated, but not 
basal, transcription in HeLa nuclear extract. Moreover, experiments using 
chemical inhibitors of proteasome-mediated proteolysis suggest that 19S 
requirement in transcription does not reflect a proteolytic event (Ferdous et al. 
2002). Furthermore, the proteasomal ATPases Sug1 and Sug2 (respectively 
Rpt-6 and Rpt-4 in mammalian) is required for efficient transcription of several 
stress-induced genes in yeast. In particular, Sug1 and Sug2 are essential for the 
efficient transcription of both heat shock and oxidative stress-responsive genes. 
When Sug1 or Sug2 activity was abolished shifting temperature-sensitive 
strains to the restrictive temperature, transcription of these genes was crippled. 
In contrast, inactivation of temperature-sensitive 20S core proteins had little or 
no detectable effect on expression of these genes (Sulahian et al. 2006).  
ChIP assay revealed the induction-dependent recruitment of the proteasomal 
ATPases, but not of the 20S core complex, to the promoter of these genes.  
Lee and coworkers (Lee et al. 2005) reported that 19S subunits can facilitate 
SAGA (Spt-Ada-Gcn5-Acetiltransferase) targeting to promoters by 
transcriptional activators and that there is a functional link between SAGA and 
the proteasomal ATPases.  
Moreover, in S. cerevisiae it was demonstrated the interaction of the 19S 
subunit of the proteasome with the ubiquitin-like N-terminus of Rad23, a 
nucleotide excision repair (NER) protein. (Russell et al. 1999).  
Rad23 is required for optimal activity of an in vitro NER system. Inhibition of 
proteasomal ATPases diminishes NER activity in vitro and increases UV 
sensitivity in vivo. 
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1.1.3 TBP-1 has a role in transcriptional regulation. 
 
As mentioned before, there are different evidences suggesting the involvement 
of 19S subunit protein members in cellular events that do not require 
proteolysis.  
In particular, TBP-1 was originally isolated in a screen for proteins interacting 
with the HIV-1-Tat protein and was reported to inhibit Tat-mediated 
transactivation of HIV-1 LTR promoter (Nelbock et al. 1990).  
More recently, Lassot and co-workers demosrated the involvement of all six 
AAA-ATPases in the control of HIV-1 transcription by both proteolytic and 
non-proteolytic mechanism (Lassot et al. 2007).  
TBP-1, although unable to bind DNA, is a strong transcriptional activator when 
brought into proximity of several promoter elements and transcriptional 
activity depends upon the integrity of the ATPase and helicase motifs (Ohana 
et al. 1993). Consistent with this assumption, TBP-1 interacts and enhances the 
HBx-specific transcription of the HBV virus (Barak et al. 2000). 
It was demonstrated that TBP-1 is also involved in transcriptional activation of 
the thyroid hormone (TR)-responsive gene.   
In particular, it directly interacts with the TR-binding protein-1 (Trip-1), a 
putative transcriptional mediator for TR that binds to the AF-2 domain of TR 
in a ligand dependent manner.  
These findings demonstrated that TBP-1 interacts not only with Tat but also 
with TR and might function as a novel DNA binding domain coactivator 
specifically involved in the TR-mediated gene activation (Ishizuka et al. 2001).  
Recently, it has been reported that TBP-1 could directly interact with androgen 
receptor (AR) in vivo and in vitro, and functionally potentiated the AR-
mediated transcriptional activation in cooperation with TBPIP (TBP-1-
interacting protein) (Satoh et al. 2009).  
Truax and co-workers (2010) demonstrated that TBP1 is crucial for regulating 
cytokine-inducible transcription of Class II Transactivator (CIITA).  
They observed that decreased expression of TBP1/S6a significantly reduces the 
recruitment of transcription factors to the CIITA interferon-?-inducible 
promoter (CIITA promoter IV (pIV)) (Truax et al. 2010). 
 
 
 
1.1.4  TBP-1 roles in the control of cell proliferation and oncosuppression. 
 
The acquisition of a transformed phenotype is a quite complex stepwise 
accumulation of genetic changes and requires the acquisition of different 
hallmark traits.   
Arguably one of the most fundamental traits of cancer cells involves their 
ability to sustain chronic proliferation (Hanahan and Weinberg 2000).  
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Abundant evidences suggest that TBP-1 may function as a negative regulator 
of cell proliferation.  
The first evidence came from Park and its co-workers (1999).  
They demonstrated that the inhibition of the oncogenic phenotype of erb-B 
transformed cells was accompanied by an increase of TBP-1 intracellular levels 
and, accordingly, its overexpression in erb-B transformed cells strongly 
inhibited tumor formation in athimic mice (Park et al. 1999). 
TBP-1 also possesses 46% identity to KAI I, a metastasis tumor suppressor 
gene for human prostate cancer (Dong et al. 1995) and maps to chromosome 
11p12-13, a region frequently deleted in cancers (Hoyle et al. 1997).  
Moreover, TBP-1 overexpression in different cellular contexts diminished cell 
proliferation (Pollice et al. 2004; Park e al. 1999). Furthermore, consistent with 
its role in protein destruction, TBP-1 has been shown to bind the tumor 
suppressor pVHL (Von Hippel Lindau), involved in the Von-Hippel-Lindau 
disease, an autosomal hereditary cancer syndrome characterized by the 
development of vascular tumors in the retina, in the central nervous system and 
in renal cell carcinoma. The TBP-1-VHL binding enhances the VHL-E3 
ubiquitin ligase activity toward the Hif1-Į factor, highly overexpressed in 
cancer cells that have to sustain growth in low oxygen concentration. In 
normoxic conditions, TBP-1 binds to VHL and stimulates its ubiquitin ligase 
activity towards Hif1-Į that is rapidly degraded by the proteasome.  
The increased expression of TBP-1 resulted in enhanced kinetics degradation 
of Hif1Į whereas its silencing impairs the VHL-mediated proteasome 
degradation suggesting the essential function of TBP-1 in Hif1Į destruction 
(Corn et al. 2003).  
More recently, TBP-1 has been shown to be directly involved in the negative 
regulation of intracellular levels of Fos related antigen-1(Fra-1). Fra-1 is the 
member of the Activator Protein-1 (AP-1) transcription factor superfamily that 
is overexpressed in a variety of human cancers and its overexpression is 
associated with enhanced cell proliferation, survival, migration and invasion.  
It was demonstrated that TBP-1 associates with and downregulates Fra-1 
intarcellular levels in cancer cells expressing oncogenic components of the 
RAS-ERK pathway that regulate Fra-1 synthesis and stability.  
In particular, TBP-1 overexpression reduces endogenous Fra-1 protein levels in 
three cancer cell lines expressing oncogenic ERK pathway components, while 
its silencing increases Fra-1 endogenous levels (Pakay et al. 2011).   
My research group highlighted a very interesting aspect regarding the  role of 
TBP-1 in the control of cell proliferation. In fact it has been demonstrated that 
TBP-1 interacts with the p14ARF human oncosuppressor increasing its half 
life. This effect requires the physical interaction between TBP-1and the first 39 
amino acids of p14ARF and does not involve the transcriptional properties of 
TBP-1 (Pollice et al. 2004). Moreover, p14ARF is degraded in vitro by the 20S 
proteasome and TBP-1 protects it from proteasomal degradation. Interestingly, 
a point mutation in the ATPase domain of TBP-1 that destroys its chaperone-
like activity, impairs TBP-¶VDELOLW\to stabilize ARF.  
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This observation suggests that this effect requires the chaperone-like activity of 
TBP-1 and leads to the hypothesis that, upon binding, TBP-1 could cause ARF 
to fold, rendering it a poor substrate for proteasome destruction (Pollice et al. 
2007). On the other hand, the observation that TBP-1 overexpression can 
inhibit cell proliferation also in ARF minus contexts  (Pollice et al. 2004; Park 
e al. 1999) suggests an ARF-independent role of TBP-1, raising the question of 
what molecular pathways may be involved.  
In this scenario, it is particularly intriguing our observation that the cellular 
levels of TBP-1 are modulated by the activation of Akt/PKB serine-threonine 
kinase, one of the major transducers of the growth signals mediating pro-
proliferative and pro-survival effects (Sepe et al. 2011). 
 
 
 
1.2 THE SERINE-THREONINE KINASE AKT/PKB. 
 
Akt/PKB is a 63 kDa serine/threonine kinase involved in the promotion of cell 
survival, proliferation and metabolic responses downstream the 
phosphoinositide-3-kinase (PI3K) signaling pathway. In 1991, the group of 
Philip Tsichlis identified v-Akt as the gene transduced by rodent retrovirus 
AKT8 (Bellacosa et al. 1991), and subsequently showed that its cellular 
homolog, then named c-Akt encoded the serine-threonine protein kinase Akt 
(Bellacosa et al. 1993). Akt/PKB was also identified by two other research 
teams that independently cloned the same sequence using approaches designed 
to identify new protein kinases related to protein kinases A and C (PKA and 
PKC) (Coffer et al. 1991).  
In mammals, three closely related isoforms of Akt are encoded by distinct 
genetic loci: Akt1/PKBĮ, Akt2/PKBȕ, and Akt3/PKBȖ, located respectively at 
chromosomes 14q32, 19q13, and 1q44.  
The three known mammalian Akt family members are differentially expressed 
at both the mRNA and protein levels (Bellacosa et al. 1993).  Akt orthologs 
have been cloned from a number of species, including Drosophila 
melanogaster and Caenorhabditis elegans (Franke et al. 1994).  
Each AKT family member contains an amino-terminal pleckstrin homology 
(PH) domain (Franke et al. 1994), a short Į-helical linker, and a carboxyl-
terminal kinase domain (Ahmed et al. 1993) (Figure 3 ).  
7KHSOHFNVWULQKRPRORJ\3+GRPDLQRI$.7NLQDVHVKDVDIILQLW\IRUWKH¶-
phosphorylated phosphatidylinositol 3,4,5-triphosphate (PIP3) produced by 
phosphatidylinositol 3 kinase (PI3K) (Franke et al. 1997).  
The kinase domain of Akt, located in the central region of the molecule, with 
specificity for serine or threonine residues in substrate proteins, shares a high 
similarity with other AGC kinases such as PKA and PKC (Peterson et al. 
1999).  
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Figure 3 Akt1,2,3/PKB?,?,? Structure. 
 
PH, Pleckstrin Homology domain; Kinase, catalityc domain 
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1.2.1 Upstream regulation of Akt kinase activity. 
 
The AKT kinases are major downstream targets of growth factor receptor 
tyrosine kinases that signal via phosphatidylinositol 3-kinase (PI3K). The 
Akt/PKB kinase has emerged as a critical mediator of signal transduction 
pathways downstream of growth factors such as platelet derived growth factor 
(PDGF) (Franke et al. 1995), insulin and insulin-like growth factor (IGF) 
(Cross et al. 1995; Kohn et al. 1995), epidermal growth factor (EGF) or basic 
fibroblast growth factor (bFGF) (Burgering and Coffer 1995).  
The PI3K-dependent activation of Akt requires two consecutive events: the 
binding of the Akt PH domain to PIP3 that induces the relocalization of the 
cytoplasmic Akt protein to signaling complexes at the plasma membrane 
(Franke et al. 1997), and the phosphorylation of two key residues, Thr-308 and 
Ser-473, that allow full activation of the kinase domain (Figure 4) (Alessi et al. 
1996).  
The Thr-308 residue is located in the activation loop and the kinase responsible 
for this phosphorylation is the phosphoinositide-dependent kinase (PDK1) 
(Alessi et al. 1997).  
More controversial is the identity of the kinase(s) responsible for Ser-473 
phosphorylation (Chen et al. 2001).  
At least 10 kinases have been proposed to function as the hydrophobic motif 
domain protein kinase (HMD-PK) that phosphorylates Akt on Ser-473, 
including protein kinase C? (PKC?) (Partovian et al., 2004), double-stranded 
DNA-dependent protein kinase (DNA-PK), and ataxia telangiectasia mutated 
(ATM) gene product (Viniegra et al. 2005).  
In most cell types and conditions the predominant kinase is the mammalian 
target of rapamycin complex 2 (mTORC2). It was recently demonstrated that 
the target of rapamycin (TOR) kinase and its associated protein Rictor are 
necessary for Ser-473 phosphorylation and a reduction in Rictor or mammalian 
TOR (mTOR) expression inhibited an Akt/PKB effector (Sarbassov et al. 
2005; Hresko et al. 2005). The activation of Akt/PKB is prevented if the cells 
are pretreated with inhibitors of PI3K (wortmannin or LY 294002) or by 
overexpression of a dominant negative mutant of PI3K (Burgering and Coffer 
1995). The PI3K/Akt axis is inactivated through the action of Phosphatase and 
tensin homolog (PTEN) protein.  PTEN is the main negative regulator of AKT 
activation and inhibits phosphoinositide 3-kinase (PI3K)-dependent signaling 
dephosphorylating phosphatidylinositol 3,4,5-triphosphate (PIP3) (Maehama et 
al. 1998).  
Another mechanism through which the PI3K/Akt axis is inactivated acts 
through dephosphorylation of  the two key residues of Akt kinase.  
The PH-domain leucine-rich repeat protein phosphatase (PHLPP) has recently 
been proposed to dephosphorylate Ser-473 (Gao et al. 2005), while the protein 
phosphatase 2A (PP2A) is known to dephosphorylate Thr-308 (Millward et al. 
1999).  
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Figure 4 Upstream activation of PI3K-Akt pathway. 
 
This figure shows the upstream activation of Akt by Growth Factors and also depicted 
is the complex relationship between Akt signaling and mTOR complex 1 and 2. 
Activated receptor tyrosine kinases (RTKs) activate PI3K. PI3K phosphorylates 
phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-
trisphosphate (PIP3), in a reaction that can be reversed by the PIP3 phosphatase PTEN. 
AKT and PDK1 bind to PIP3 at the plasma membrane, and PDK1 phosphorylates the 
activation loop of AKT at Thr-308. 
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1.2.2 Akt targets and cellular functions. 
 
The multiplicity of Akt functions might be due to the variety and specificity of 
its substrates involved in different cellular functions. The minimal substrate 
consensus sequence for Akt, RXRXXS/T, where X is any amino acid and S/T 
is the phosphorylation site, is based on the sequence around the 
phosphorylation site on glycogen synthase kinase 3 beta (GSK3?), the first 
identified substrate (Datta et al. 1999).  
Akt-mediated phosphorylation leads to the activation or inhibition of protein 
targets contributing to the activation of various interrelated cellular processes 
(cell survival, cell proliferation, growth (size), glucose uptake, metabolism, and 
angiogenesis) (Figure 5).  
 
 
 
Figure  5  Cellular functions of ten Akt substrates. 
 
Akt-mediated phosphorylation of these proteins leads to their activation (arrows) or 
inhibition (blocking arrows). Regulation of these substrates by Akt contributes to 
activation of the various cellular processes shown (i.e., survival, growth, proliferation, 
glucose uptake, metabolism, and angiogenesis). 
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¾ Akt-dependent control of cell survival.  
 
Several groups have independently demonstrated a critical role for Akt in 
promoting cell survival downstream of growth factors, oncogenes, and cell 
stress, by blocking the function of pro-apoptotic proteins and processes.  
Protein database analysis reveals a large number of mammalian proteins that 
contain Akt consensus phosphorylation sites (RXRXXS/T). Among these 
proteins there are several components of the apoptotic machinery.  
It was demonstrated that Akt negatively regulates the function or expression of 
several Bcl-2 homology domain 3 (BH3)-only proteins, which exert their pro-
apoptotic effects by binding to and inactivating pro-survival Bcl-2 family 
members.  Akt directly phosphorylates and inhibits the BH3-only protein BAD 
(Datta et al. 1997). Survival factors stimulate Akt-mediated phosphorylation of 
BAD on Ser-136, creating a binding site for 14-3-3 proteins, triggering release 
of BAD from its target proteins (Datta et al. 2000).  
Akt has also been found to directly phosphorylate Ser-196 on human 
procaspase-9, and this phosphorylation correlates with a decrease in the 
protease activity of caspase-9 in vitro (Cardone et al. 1998).  
Moreover, Akt promotes cell survival by phosphorylating and restricting the 
nuclear entry of transcription factors of the Forkhead family (FOXO), 
preventing transcription of pro-apoptotic genes such as the Fas ligand (Brunet 
et al. 1999).  
It is also possible that Akt exerts some of its cell-survival effects through 
crosstalk with other pathways. For instance, it has been reported that, under 
some conditions, the PI3K-Akt pathway activates NFkB survival signaling or 
inhibits JNK/p38 apoptotic signaling (Kim et al. 2001; Ozes et al. 1999).  
Furthermore, AKT counteracts apoptosis promoting phosphorylation of the 
murine double minute 2 (MDM2) oncoprotein, the E3 ubiquitin ligase that 
triggers p53 degradation.  
In 2001, Mayo and Donner demonstrated that mitogen-induced activation of 
PI3K and its downstream target, the Akt kinase, results in a phosphorylation of 
MDM2 on two serine residues (S166 and S186) (Mayo and Donner 2001). 
These Akt phosphorylation sites in MDM2 are close to the nuclear localization 
signal (NLS) and nuclear export signal (NES), which are required for MDM2 
to shuttle between the nucleus and the cytoplasm.  
Phosphorylation promotes translocation of MDM2 from the cytoplasm to the 
nucleus, where it negatively regulates the p53 function (Mayo and Donner 
2001; Zhou et al. 2001a). There are still disagreements on which are the target 
residues important for MDM2 phosphorylation and translocation from the 
cytoplasm to the nucleus. In fact another group has shown that Akt 
phosphorylates MDM2 at Serine 186 and this phosphoryation does not affect 
the subcellular localization of MDM2 (Ogawara et al. 2002).  
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¾ Akt-dependent control of cell proliferation.  
 
The proliferative effect of Akt is mediated by multiple mechanisms. Several 
groups have independently found that Akt phosphorylates the p27
Kip1
 cyclin-
dependent kinase inhibitor on threonin 157 (Liang et al. 2002; Shin et al. 2002; 
Viglietto et al. 2002). This phosphorylation leads to cytosolic sequestration of  
p27 preventing its localization to the nucleus (Sekimoto et al. 2004).  
Akt also inhibits p27 expression through phosphorylation and inhibition of the 
FOXO transcription factors (Medema et al. 2000).  
Consistently, Akt has also been found to phosphorylate the cyclin-dependent 
kinase inhibitor p21
Cip1/WAF1
. In breast cancer cells exhibiting Akt activation 
due to HER-2/neu overexpression, phosphorylation by Akt prevents nuclear 
localization of p21
Cip1/WAF1
, separating this cell cycle inhibitor from its 
cyclin/cyclin-dependent kinase targets (Zhou et al. 2001b).  
Furthermore, Akt-dependent phosphorylation of targets such as the glycogen 
s\QWKDVH NLQDVH  EHWD *6.ȕ also affected cell proliferation through 
regulation of the stability of proteins involved in cell-cycle entry.  
Akt prevents degradation of the cyclins D1 and E that play a central role in the 
G1-S phase cell-F\FOHWUDQVLWE\SKRVSKRU\ODWLQJDQGLQKLELWLQJ*6.ȕNLQDVH
activity (Diehl et al. 1998).  
Akt signaling also controls the translation of proteins important for cell-cycle 
progression, predominantly through the activation of mammalian target of 
rapamycin complex 1 (mTORC1).  
The predominant cellular effect of mTORC1 inhibitors, such as rapamycin, is 
to cause a G1 cell-cycle arrest, and Akt mediated cell proliferation and 
oncogenic transformation has recently been shown to be dependent on 
mTORC1 activation (Skeen et al. 2006).  
In some cell lines, Akt activity has been shown to be elevated during the G2/M 
phase of the cell cycle, and Akt activation promotes progression through 
mitosis, even in the presence of DNA damage (Kandel et al. 2002).  
One mechanism explaining this observation is that Akt directly phosphorylates 
the DNA damage checkpoint kinase Chk1 (King et al. 2004).  
This phosphorylation blocks checkpoint function by stimulating Chk1 
translocation to the cytosol, where it is sequestered from the DNA damage-
sensing kinases ATM and ATR (Puc et al. 2005).  
 
 
 
¾ Akt-dependent control of cell growth.  
 
One of the best-conserved functions of Akt is its role in promoting cell growth 
(an increase in cell mass). The predominant mechanism appears to be through 
activation of Mammalian target of rapamycin complex 1 (mTORC1) which is 
regulated by both nutrients and growth factors signaling.  
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MTORC1 is a critical regulator of translation initiation and ribosome 
biogenesis and plays an evolutionarily conserved role in cell growth control. 
Akt phosphorylates and inhibits the function of tuberous sclerosis complex 
(TSC2), a critical negative regulator of mTORC1 signaling (Inoki et al. 2002).  
 
 
 
¾ Akt-dependent control of angiogenesis.  
 
Akt plays an important role also in both physiological and pathological 
angiogenesis through effects in both endothelial cells and cells producing 
angiogenic signals, such as tumor cells. Akt activates endothelial nitric oxide 
synthase (eNOS) through direct phosphorylation of Ser-1177 (Dimmeler et al. 
1999; Fulton et al. 1999). The release of nitric oxide (NO) produced by 
activated eNOS can stimulate vasodilation, vascular remodeling, and 
angiogenesis.  
Akt signaling also leads to an increased production of the hypoxia-inducible 
factor ? (HIF1-? and HIF2-?) transcription factors (Toschi et al. 2008). HIF-? 
activation in endothelial and other cells leads to expression and subsequent 
secretion of VEGF and other angiogenic factors, thereby stimulating 
angiogenesis.  
 
 
 
¾ Akt-dependent control of glucose uptake. 
  
One of the most important physiological function of Akt is to acutely stimulate 
glucose uptake in response to insulin. Akt2, the primary isoform in insulin-
responsive tissues, has been found to associate with glucose transporter 4 
(Glut4)-containing vesicles upon insulin stimulation of adipocytes (Calera et al. 
1998), and Akt activation leads to Glut-4 translocation to the plasma membrane 
(Kohn et al. 1996).  
 
 
 
¾ Akt-dependent control of cell migration and invasion. 
 
AKT has also been shown to contribute to tumor invasion and metastasis by 
promoting the secretion of matrix metalloproteinases (Thant et al. 2000). More 
recently, Grille and co-workers show that Akt activation determines Epithelial-
mesenchymal transition (EMT) characterized by down-regulation of numerous 
epithelial cell-specific proteins, including E-cadherin and ?-catenin, and 
upregulation of the mesenchymal cell-specific protein vimentin. Interestingly, 
they showed that EMT was accompanied by increased in vivo cell motility on 
20 
 
fibronectin-coated surfaces and increased invasiveness in animals, incresing 
even more the spectrum of  Akt biological activities (Grille et al. 2003). 
 
 
 
1.2.3 Activation of Akt  plays a central role in tumorigenesis. 
 
Akt signaling regulates cell proliferation and survival, cell growth (size), 
glucose metabolism, cell motility and angiogenesis. Aberrant regulation of 
these processes results in cellular perturbations considered hallmarks of cancer, 
and several studies suggest the frequent alteration of AKT gene in many human 
cancers (Table 1).   
In 1992, the group of Cheng reported the first recurrent involvement of an 
AKT gene in a human cancer, demonstrating amplification and overexpression 
of AKT2 in ovarian tumors and cell lines (Cheng et al. 1992).  
Subsequent studies documented AKT2 amplification and/or mRNA 
overexpression in 10±20% of human ovarian and pancreatic cancers (Bellacosa 
et al. 1995; Cheng et al. 1996) and activation of the AKT2 kinase in 40% of 
ovarian cancers (Yuan et al. 2000).  
Unlike AKT2, amplification of AKT1 has not been reported as a frequent event 
in any tumor type. AKT1 amplification was initially detected in a human 
gastric carcinoma (Staal et al. 1987), and a more recent investigation of 103 
malignant glial tumors revealed a single case (a gliosarcoma) with 
amplification and overexpression of AKT1 (Knobbe and Reifenberger 2003). 
Likewise, AKT1 protein levels have been reported to be elevated in some types 
of cancer, even though the gene is rarely amplified. An immunohistochemical 
analysis of a series of breast cancers revealed elevated AKT1 staining in 24% 
of tumors, while strong AKT2 staining was evident in only 4% of tumors (Stal 
et al. 2003).  
AKT1 kinase activity is often increased in prostate and breast cancers and is 
associated with a poor prognosis (Sun et al. 2001).  
AKT3 mRNA is upregulated in estrogen receptor-negative breast tumors, 
increased AKT3 enzymatic activity was found in estrogen receptor-deficient 
breast cancer and androgen-insensitive prostate cancer cell lines (Nakatani et 
al. 1999). More recently, an AKT3 gene amplification in estrogen receptor-
positive breast carcinomas has been described (Kirkegaard et al. 2010).   
Several oncoproteins and tumor suppressors intersect in the AKT pathway, 
finely regulating cellular functions at the interface of signal transduction and 
classical metabolic regulation. This careful balance is altered in human cancer 
by a variety of activating and inactivating mechanisms that target both AKT 
and interrelated proteins. Various mechanisms contribute to activation of the 
AKT pathway in human tumors, including loss or down-regulation of PTEN 
function and amplifiacation/up-regulation of the PI3KCA gene (which encodes 
the catalytic subunit of PI3K) (Shayesteh et al. 1999).  
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Loss of PTEN function leads to an elevated concentration of the PIP3 substrate, 
and consequent constitutive activation of downstream components of the PI3K 
pathway, including the AKT and mTOR kinases. Somatic mutation and 
biallelic inactivation of PTEN occur frequently in high-grade glioblastoma, 
melanoma, and cancers of the prostate and endometrium (reviewed in Sansal 
and Sellers 2004).  
Other mechanisms resulting in activation of the AKT pathway in human 
cancer, include activation of PI3K due to autocrine or paracrine stimulation of 
receptor tyrosine kinases (Tanno et al. 2001) and overexpression of growth 
factor receptors such as the epidermal growth factor receptor in glioblastoma 
multiforme (Schlegel et al. 2002) or HER-2/neu in breast cancer (Bacus et al. 
2002). 
 
TABLE 1. Hallmarks of cancer and multiple roles of AKT. 
 
Testa J. R. and.  Bellacosa A. ³$.7SOD\VDFHQWUDOUROHLQ
WXPRULJHQHVLV´31$6 10983±10985. 
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2. PRELIMINARY DATA AND AIM OF THE STUDY 
 
Several observations point to the involvement of TBP-1 in the control of cell 
proliferation and oncosuppression. Among these, my research group 
highlighted a very interesting aspect regarding TBP-1 that turned out to be a 
regulator of the p14ARF human oncosuppressor (Pollice et al. 2004; Pollice et 
al. 2007). In particular, this effect requires the physical interaction between 
ARF and TBP-1 and does not involve its transcriptional properties.  
Actually, TBP-1 is able to counteract the degradation of p14ARF by the 20S 
proteasome in vitro, independently from the presence of an assembled 19S 
particle.  
Interestingly, a point mutation in the ATPase domain of TBP-1 that destroys its 
chaperone-like activity, impairs TBP-¶V DELOLW\ WR VWDELOL]H $5) VXJJHVWLQJ
that this effect requires the chaperone-like activity of TBP-1 (Fabio Tolino, 
personal communication).  
We and other groups (Park et al. 1999; Corn et al. 2003; Pollice et al. 2004 and 
2007; Pakay et al. 2011; Sepe et al. 2011) reported that TBP-1 may function as 
a negative regulator of cell proliferation in various cellular contexts also 
independently by the presence of ARF.  
These observations not only further underlie the antiproliferative role of TBP-1 
but suggest that it can exert a more general ARF-independent role in the 
control of cell proliferation raising the question of what kind of molecular 
pathways may be involved.  
My research project is focused on the antiproliferative role exerted by TBP-1 
and the analysis of molecular pathways involved.  
To this aim I used, as a model, a primary human fibroblast cell line expressing 
undetectable levels of p14ARF, the T11hT cell line, immortalized by h-TERT 
(human telomerase catalytic subunit) expression. TBP-1 intracellular levels 
were reduced in these cells by the constitutive expression of a specifically 
designed shRNA.  
My results show that cellular levels of TBP-1 are critical in the control of cell 
proliferation, according to its potential tumor suppressive functions, and 
suggest the existence of a functional relationship between TBP-1 and the 
Akt/PKB serine-threonine kinase, one of the major transducers of growth 
signals, crucial in development of cancer. 
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3. MATERIALS AND METHODS 
 
Constructs  
pSUPERIORshTBP-1 has been obtained from pSUPERIOR.retro.neo (Oligoengine) 
by cloning into BglII-HindII sites a duplex oligonucleotide obtained by MWG-Biotech 
that could give rise to a short hairpin RNA specifically designed to silence TBP-1 
expression.  
Oligoseq:
¶
GATCCCCAACAAGACCCTGCCGTACCTTCAAGAGAGGTACGGCA
GGGTCTTGTTTTTTTA
¶ 
pCA-Akt plasmid was kindly provided by Prof. G. Condorelli.  
The MDM21-441 and MDM2'150-230 expression plasmids were previously 
described (Jin et al., 2003).  
Plasmids MDM2S166A and MDM2S166A/S186A mutant were generated by Quick 
Change Site Direct Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following 
WKHPDQXIDFWXUHU¶VLQVWUXFWLRQ 
Briefly, pCMV MDM2 plasmid (with target site for mutation) was denatured.   
After the annealing of the mutagenic primers: 
 
S166A (F)  
¶
GGAGAGCAATTGCTGAGACAGAAG 
¶
, 
S166A (R)  
¶
CTTCTGTCTCAGCAATTGCTCTCC 
¶
 
S166A/S186A (F) 
¶
 CGCCACAAAGCTGATAGTATTTCCC 
¶
 
S166A/S186A (R)
 ¶
GGGAAATACTATCAGCTTTGTGGCG
¶
 
 
a PCR reaction was performed with a 2720 Thermo Cycler Applied Biosystem, 
resulting in a nicked circular strands.  
The addition of DpnI to the reaction causes the digestion of the methylated, 
non mutated DNA template.  
DpnI treated DNA from sample reaction was transferred to 50 µl of super-
competent cells. After transformation, the super-competent cells repair the 
nicks in the mutated plasmid. 
 
 
 
Cell culture and transfection. 
 
T11hT (human primary fibroblasts immortalized by costitutive expression of 
the telomerase catalytic subunit h-TERT) human cell line was kindly provided 
by dr. Eric Gilson. Both T11hT and TBP-1 silenced clones were grown in 
'XOEHFFR¶V0RGLILHG(DJOH0HGLXP'0(0VXSSOHPHQWHGZLWK)HWDO
Bovine serum and 1 mg/ml puromycin (to maintain selection for h-TERT). 
U2OS and MEFs p53-/MDM2- FHOOV ZHUH JURZQ LQ 'XOEHFFR¶V 0RGLILHG
EagleMedium supplemented with 10% Fetal Bovine serum.  
TBP-1 silenced cells derived by retroviral infection of T11hT: briefly, 3x10
6
 
HEK 293-LinX packaging cells (kindly provided by Prof. Nicola Zambrano) 
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were transfected with ARREST-IN (Open Biosystems, Huntsville, AL, USA) 
with pSUPERIOR.shTBP-1. 24 hrs after transfection, virus containing 
supernatant was filtrated through 0,45 mm cellulose acetate syringe filter, 
supplemented with 5 mg/ml polybrene, and used to infect recipient T11hT 
cells, previously plated at 50% confluence. Twenty-four hours following 
infection, 1 mg/ml G418 was applied to select stably infected cells. After four 
weeks, resistant cells were collected, expanded and analyzed. Transfection of 
the T1 clone was performed by the use of a Microporator MP-100 (Digital Bio 
Technology) using either 2x10
6 
cells with 2 µg of either pcDNA empty vector 
or pcDNATBP-1. Transfection of U20S and MEF cells was performed by 
Lipofectamine 2000 (Invitrogen) according to WKHPDQXIDFWXUHU¶VLQVWUXFWLRQV 
 
 
 
Protein extraction, Western Blotting and antibodies. 
After transfection, cells were lysed in RIPA Buffer (50 mMTris-HCl pH 7.5, 5 
mM EDTA, 150 mM NaCl, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, 
0.5% sodium deoxycholate, and protease inhibitors). Cell lysates were 
incubated on ice for 40 minutes, and the extracts were centrifuged at 13,000 
rpm for 15 minutes to remove cell debris.  
Protein concentrations were determined by the Bio-Rad protein assay.  
After the addition of 2x Laemmli buffer (SIGMA), the samples were boiled at 
100°C for 5 minutes and resolved by SDS-polyacrylamide gel electrophoresis. 
Proteins were transferred to a polyvinylidene difluoride membrane (Millipore) 
probed with the primary antibodies described in the results (2 hours at room 
temperature or over night at 4°C), followed by incubation with the horseradish 
peroxidase secondary antibodies (1 hour at room temperature).  
Antibodies to Akt (used in 1:1000 dilution), Phospho-Akt Ser473 (used in 
1:1000 dilution), Phospho-GSK-3b/pSer21/9 (used in 1:1000 dilution), 
Caspase-3 (1:1000), PTEN (1:1000) and PARP-1 (1:1000) were purchased 
from Cell Signalling Technologies, Boston, MA, USA. Antibodies to MDM2 
(used in 1:500 dilution) was purchased from Calbiochem, to Rpt-1 (PSMC2) 
(used in 1:6000 dilution), Rpt6 (PSMC5) (used in 1:6000 dilution) and C8 
(used in 1:6000 dilution) were purchased from BioMol. Anti-Xpress antibody 
(used in 1:1000 dilution) was purchased from Invitrogen. Secondary antibodies 
for Western Blot analysis (goat anti-rabbit IgG-HRP 1:3000 dilution) were 
purchased from Santa Cruz Biotechnology, CA, USA. Proteins were visualized 
with an enhanced chemiluminescence detection system (Amersham ECL TM) 
and images were taken with ChemiDoc XRS System (Bio-Rad Laboratories) 
and analysed with the QuantityONE software. 
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Immunoprecipitation. 
For immunoprecipitation in U2OS cells, 1x10
6
 cells were seeded in 100 mm 
dishes and transfected with the plasmids indicated in the figure legend. Cells 
were harvested 24 hours post-transfection, lysed in IBP buffer (150 mM NaCl, 
50 mM Tris-HCl, 0.5% Nonidet P-40, , 5mM EDTA, 10% glycerol, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and protease inhibitors). 800 µg of 
whole cell extract were incubated overnight at 4
0
C with anti-TBP1 (BioMol) or 
anti-MDM2 C-18 (Santa Cruz). Controls of immunoprecipitations were 
perceived with mouse anti-GFP (Roche) or rabbit anti-Flag (Sigma). 
Immunocomplexes were collected by incubation with 30 ml of protein A-
agarose (Roche Applied Science) at 4
o
C for 4 hrs. The beads were collected by 
centrifugation, and the immunoprecipitates were washed three times with IBP 
buffer (4 °C), solubilized in Laemmli buffer (Sigma) and loaded on a SDS-8% 
polyacrylamide gel. 
 
 
 
siRNA of TBP-1. 
A duplex siRNA oligomer designed to target human TBP-1 was obtained by 
MWG Biotech according to Corn et al. (2003).  
The siRNA sequence for TBP-1 used is : 
¶-AACAAGACCCUGCCGUACCUU-¶ FRUUHVSRQGLQJ WR SRVLWLRQ  LQ
the PSMC3 mRNA. As negative control a siRNA targeting a sequence firefly 
luciferase mRNA was used. U20S and T11HT cells were transfected with 
+\SHUIHFW 4XLDJHQ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV DSSO\LQJ
siRNA duplex at final concentrations of 10 µM. Western blots were performed 
with anti-TBP-1 and anti-pAkt antibodies. 
 
 
 
siRNA of MDM2. 
A duplex siRNA oligomer designed to target human MDM2 was obtained by 
MWG Biotech according to Jin et al. (2003).  
The siRNA sequence for MDM2 used is:  
¶- AAGCCAUUGCUUUUGAAGUUA-¶ 
U20S cells were transfected with Hyperfect (Quiagen) according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV DSSO\LQJ VL51$GXSOH[DW ILQDO FRQFHQWUDWLRQVRI
10 nM. Western blots were performed with anti-MDM2, anti-TBP-1 and anti-
pAKT Ser473 (Cell Signalling 9271). 
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Treatment with proteasome inhibitor. 
2,5x10
5 
U2OS cells were seeded into 35-mm plates and transfected with 
pcDNA TBP-1 either alone or in combination with incresing amount of  
pcMVMDM2 expression plasmids. The following day, each plate was treated 
for 5 hours with 10 µM MG132 (Sigma) and with 0.1% dimethyl sulfoxide 
(Sigma) as control. Cell lysates were collected and probed with anti-TBP-1, 
anti-MDM2 and anti-actin antibodies.  
 
 
 
Treatment of the cells with PI3K inhibitors.  
2,5x 10
5 
T11HT and U20S cells were plated in 35 mm dishes.  
24 hours after  plating, cells were treated with Wortmannin (Calbiochem) at the 
concentration of  200 nM for 1, 2 and 4 hours. Total cell extracts were prepared 
as described above and samples were analyzed by Western blot. LY294002 at 
the concentration of 50mM for 1, 2 and 4 hours. 
 
 
 
Treatment of the cells with insulin.  
U2OS and T11HT cells were plated in 35 mm dishes.  24 hours after plating, 
cells were starved for four hours in serum free medium and then stimulated 
with insulin at the concentration of 10 ng/ml for 5, 10, 20, 30 and 40 minutes. 
Cells were harvested and analyzed by Western Blot with antibodies indicated 
in the Results. 
 
 
 
Cell growth analysis. 
For cell growth analysis, T11hT parental cell line, T1 and T10C  clones, or 
control pool and sh-TBP-1 pool, were plated in 100 mm dishes in presence of 
10% FBS at the cell density of 1x10
5
 cells/plate. Cells were cultured for 24, 48 
and 72 hrs, collected, and counted in a Burker chamber.  
For growth in the absence of serum, after 6 hrs from plating, medium was 
removed and replaced with medium without serum.  
As above, cells have been grown for 24, 48 and 72 hrs, collected and counted. 
Each point is the result of triplicate samples. 
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MTS assay. 
Cell viability was evaluated using the MTS [3-(4,5-dimethylthiazhol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,inner salt] (Cell 
Titer 96AQueous assay G358purchased from Promega) colorimetric assay. 
Briefly, T11hTparental cell line or cells derived from the T1 clone were plated 
atdifferent cell densities as indicated in 96 well plates (2.5x10
3
/well,10
3
/well, 
3x10
2
 /well) either in DMEM or in DMEM+10%FBS. After six hrs from 
plating, 1:5 MTS solution was added to each well and the cells were incubated 
IRU ¶ DW 0C. Plates were read on a Microplate Reader (BIO-TEK 
Instruments, Model Elx800) at 492 nm. Survival was expressed as the 
percentage of viable cells in treated samples relative to non-treated control 
cells. All the experiments were repeated in quintuplicate. 
 
 
 
Flow cytometry.  
For flow cytometry analysis, T11hT and T1 cells were counted and seeded at 
210
5
cells/35 mm plate. At 24 hours after plating the medium was replaced and 
the cells treated with DMEM containing 10% Fetal bovin serum or DMEM 
without serum. At the indicated time points, cells were collected, centrifuged, 
washed twice with PBS 1x and then fixed with ice-cold 70% ethanol. Fixed 
cells were incubated with staining buffer solution (50 µg/ml PI and 50 µg/ml 
RNase A in PBS pH 7 IRU¶DW URRPWHPSHUDWXUH LQDGDUNER[6WDLQHG
cells were analysed in a fluorescence-activated cytometer (DakoCytomation). 
Data on DNA cell-content were acquired on 20,000 events at a rate of 150+/-50 
events/second and the percentages of cells in the SubG1, G0±G1, S and G2±M 
phases were quantified with Summit v4.1 software. 
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4. RESULTS AND DISCUSSION 
 
4.1 TBP-1 stable silencing determines an increase in the growth properties. 
 
As a first attemp to analyze the role of TBP-1 in the control of cell proliferation 
we studied, in collaboration with Maria Sepe, the effects of its long term 
silencing in an human primary fibroblast cell line (T11hT) immortalized by the 
stable expression of the catalytic subunit of human telomerase. 
T11hT cells were either transfected with the pSUPERIOR.shTBP-1.neo or 
pSUPERIOR.retro.neo empty vector (see Materials and Methods).  
Twenty-four hours following transfection, 1 mg/ml G418 was applied to select 
cells. After four weeks of selection, resistant cells were collected and 
expanded; the extent of TBP-1 silencing was then evaluated in cell pools. 
As it is shown in Figure 6A, TBP-1 is efficiently silenced in the T11hT cell 
pool containing the pSUPERIORshTBP-1 vector.  
The growth rate of the T11hT cell pool was then compared to that of the 
control pool and to that of the T11hT parental cells.  
To this purpose T11hT cells, control and sh-TBP-1 pools were plated in the  
presence of serum for 24, 48 and 72 hrs.  
In parallel, after 6 hrs from plating, the medium was removed, replaced with 
medium without serum and cultured for 24, 48 and 72 hrs.  
Figure 6B shows that TBP-1 silenced cells proliferate at higher rate respect to 
the parental T11hT and respect to control cells (Figure 6B).  
Importantly, VHUXPGHSULYDWLRQGRHVQ¶WDSSUHFLDEly alter the growth rate of the 
TBP-1 silenced cells that continue to proliferate, although at a less extent, 
while control cells tend to stop proliferating (Figure 6C). 
We also derived single clones resistant to neomycin selection. Six stable clones 
were analyzed and in all of them TBP-1 is silenced, with an extent of silencing 
ranging from 80% to 48% (Figure 7A). In order to exclude that reduced 
expression of TBP-1 may have altered the proteasome composition, as it was 
described in Drosophila melanogaster (Wojcik and De Martino 2002), 
intracellular protein levels of proteasome subunits other than TBP-1 was 
analysed by Western Blot in three of the silenced clones (T1, T10E and T10C). 
Figure 7B shows that the levels of expression of three different proteasome 
subunits (Rpt-6, Rpt-1 of the 19S subunit and C8 of the 20S subunit) do not 
change significantly as compared to that of the parental T11hT.  
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Figure 6 TBP-1 stable silencing determines an increase in the growth 
properties. 
 
(A) T11hT cells stably transfected with pSUPERIOR.shTBP-1 or 
pSUPERIOR.retro.neo vector were cultured in DMEM +10%FBS for 24 hrs. Levels 
of TBP-1 expression were evaluated with anti-TBP-1 antibody on whole protein 
lysates. (B,C) wt T11hT cells, cells from control or from the sh-TBP-1 cell pool were 
cultured in DMEM either in the presence (B) or in absence (C) of serum. Cells were 
collected at the time points indicated and counted in a Burker chamber. The values are 
the mean + SE of three experiments performed in triplicate.  
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Figure 7 Characterization of TBP-1 silenced clones. 
 
A, B: Cells stably transfected with TBP-1 sh-RNA vector or control cells (wt T11hT) 
were cultured in DMEM +10%FBS for 24 hrs. Levels of TBP-1 expression were 
evaluated by Western Blot with anti-TBP-1 on whole protein lysates. B: As control, 
protein levels of other proteasome components (two 19S-ATPases, Rpt-1 and Rpt-6, 
and a 20S component, C8) was evaluated in the clones T1, T10C and T10E. Bands 
intensity was evaluated by ImageQuant analysis on at least two different expositions 
to assure the linearity of each acquisition, each normalised for the respective actin 
values. Asterisk, fold value is expressed relative to the reference point (i.e. TBP-1 
levels in T11hT cells), arbitrarily set to 1. Representative of at least four independent 
experiment. 
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The growth profile of the T1 and T10C clones, with different TBP-1 residual 
expression levels, was then analyzed and compared to that of the T11hT 
parental cells. As shown in Figure 8, TBP-1 silenced clones proliferate at 
higher rate respect to the T11hT cells. In particular, the T1 clone, expressing 
very low TBP-1 levels, grows at a rate that is roughly twice that of the parental 
cell line (Figure 8A). Moreover, TBP-1 silenced cells display the same growth 
profile, both in the presence (A) and in the absence of serum (Figure 8B). 
 
 
 
Figure 8 TBP-1 knockdown determines an increase in the growth 
properties. 
 
A, B: Cells from the T1, T10C and control cells (wt T11hT) were cultured in DMEM 
either in the presence (A) or in absence (B) of serum. Cells were collected at the time 
points indicated and counted in a Burker chamber. The values are the mean + SE of 
three experiments performed in triplicate. 
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4.2 TBP-1 silencing determines resistance to serum deprivation induced 
apoptosis. 
 
Normal cells require mitogenic growth signals before they can move from a 
quiescent state into an active proliferative state.  
These signals are transmitted into the cell by transmembrane receptors that 
bind distintive classes of signaling molecules: diffusible growth factors, 
extracellular matrix components, and cell-to-cell adhesion/interaction 
molecules.  
Normal cell can not proliferate in the absence of such stimulatory signals.  
The ability to sustain chronic proliferation even in the absence of growth 
factors is one of the fundamental features of cancer cells that generate many of 
their own growth signals, thereby reducing their dependence on stimulation 
from their normal tissue microenvironment (Hanahan and Weinberg 2000).  
For this reason, the capacity of the sh-TBP-1 cell pool and of TBP-1 silenced 
clones to actively proliferate even in the absence of serum, prompted us to 
measure the cell viability of the T1 clone by a MTS assay (see Material and 
Methods).  
T11hT parental cell line or cells derived from the T1 clone were plated at 
different cell densities, (2.5 x 10
3
/well, 10
3
/well, 3 x 10
2
 /well) as indicated in 
Figure 9A and B, either in presence or absence of serum.  
After six hrs from plating, the assay was performed and survival was expressed 
as the percentage of viable cells relative to non-treated control cells.  
The Figure shows that the cell viability of the T1 clone is almost unaffected 
after 6 hrs of serum withdrawal at the higher cell density, being reduced only 
up to 60% at the lowest cell density (Fig. 9B).  
T11hT cell viability was reduced to 10% at the lowest cell density (Figure 9A). 
Serum withdrawal represents a potent trigger to induce caspase-dependent 
apoptosis in several cellular system including mouse fibroblast (Simm et al. 
1997; Schäfer et al. 2002).  
For this reason T11hT parental cells and T1 clone cells were grown for 24 
hours in presence or in absence of serum and the protein lysates were analyzed 
by Western Blot. 
According to the previous observation, the T1 clone is more resistant to serum-
deprivation induced apoptosis respect to the parental cells, as assessed by the 
very faint amounts of both Caspase-3 and PARP-1 cleavage (Figure 10A). 
Subsequently, the cell growth profile was analyzed by flow cytometry analysis. 
To this purpose, T11hT and T1 cells were plated in the presence or absence of 
serum for 24 hours. In Figure 10B, the histogram from one representative 
experiment is shown.  
On the right are shown the ratios between cells in sub-G1 or S phase in the 
absence and in the presence of serum, that highlight the different behaviour of 
T1 cells respect to control cells, when grown in absence or presence of serum. 
This analysis indicates that serum starvation only slightly affects the 
percentage of T1 cells in S phase (8% reduction), while more drastically 
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reduces that of the parental cell line (55% reduction) (Figure 10B). 
Furthermore, the increase of the sub-G1 population (of around 1.8 fold for the 
T1 clone and 3,14 fold for the parental cell line) is consistent with PARP-1 and 
Capase-3 cleavage data (Figure 10A). 
 
 
 
Figure 9 TBP-1 silencing reduces sensitivity to serum starvation. 
 
A,B: Cells from the T1 clone (B) and control cells (A) (wt T11hT) were plated at 
different cell densities as indicated, either in the presence or absence of serum. After 
six hrs from plating, cell viability was measured by MTS assay. In the histograms, cell 
viability is expressed as relative to controls, arbitrarily set to 100 (%). The values are 
the mean + SE of three experiments performed in quintuplicate. 
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Figure 10 TBP-1 silencing determines resistance to serum deprivation 
induced apoptosis. 
 
A: 1.8 x 10
5 
cells/35 mm plates from the T1 clone and control cells (wt T11hT) were 
plated in  presence of 10% FBS. 24 hours after plating were cultured in presence 
(+FBS) or absence(-FBS) of serum. Apoptosis was checked by detection of Caspase-3 
and PARP-1 cleavage (A) in Western Blot.  
B: T11hT and T1 cells were counted and seeded at 2 x 10
5
cells/35 mm plate in  
presence of 10% FBS. Cells were cultured in presence or absence of serum for 24 
hours.  Subsequently were collected and treated for analysis of cellular DNA content 
by flow cytometry. Percentages of cells in the SubG1, G0±G1, S and G2±M phases 
were quantified with Summit 4.1 software. The numerical ratios reported on the right 
is the ratio between cells in sub G1-S phase in the absence of serum and cells in the 
presence of serum.  
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4.3 TBP-1 intracellular levels affect the activation status of Akt/PKB 
kinase. 
 
The observation that TBP-1 stable depletion increases cells proliferation and 
resistence to apoptosis raises the question of which are the potential 
intracellular pathways underlying the observed phenomenons. To investigate 
this point we wondered if the extent of TBP-1 expression may regulate the 
activation status and/or the levels of expression of proteins involved in the 
control of cell proliferation.  
In particular, as a first attempt, was assessed the activation status of one of the 
major transducers of growth signals, critical for cell proliferation and 
apoptosis.  
To this aim, the levels of activation of the Akt (phospho-Akt)/PKB kinase was 
evaluated both in cell pool and in two of the silenced clones (T1 and T10C) 
under actively growth conditions (i.e. in the presence of serum).  
As shown in Figure 11A, pAkt levels are inversely correlated to the extent of 
TBP-1 silencing, being lower in the parental T11hT and in control pool and 
higher in the TBP-1 silenced cells (T1, T10C and shTBP-1 pool).  
Consistently, there is an increase in the extent of phosphorylation of GSK3E, a 
well known Akt/PKB direct target.  
Interestingly, TBP-1 reduction appears to specifically affect Akt activation but 
not that of other important transducers of growth signals, like ERK1/2. 
Importantly, we could reproduce the same effect after transient reduction of 
TBP-1 levels by siRNA duplex designed to specifically silence TBP-1 
expression (see Materials and Methods).  
Figure 11B and C shows that silencing of TBP-1 is accompanied by a 
concomitant increase in the steady-state level of pAkt in both T11hT and 
U2OS cells, indicating that this effect was not cell-specific.  
This data suggest the existence of a causal relationship between TBP-1 levels 
and Akt activation. 
Since TBP-1 silencing determines an increase in the activation status of the 
Akt/PKB kinase, we asked whether TBP-1 depletion could be causative of this 
effect.  
To this aim we VHWXSD³UHVFXH´H[SHULPHQWLQWKH7FORQHFHOOVLQZLFKZH
re-established high TBP-1 levels by transient overexpression. T1 cells were 
transfected with a fixed amount of either pcDNA empty vector or pcDNATBP-
1 and cultured in presence or in absence of serum for 24, 48 and 72 hrs.  
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Figure 11  TBP-1 knockdown determines activation of the Akt/PKB 
kinase.  
 
A: Cells from the T1, T10C, shTBP-1 pool and control cells (wt T11hT and control 
pool) were cultured in DMEM + 10%FBS for 24 hrs. Activation of Akt/PKB was 
revealed with anti-Phospho-Akt (Ser-473) antibody. As control, extracts were also 
probed with anti-Akt, anti-Phospho-GSK-3E (Ser-219), anti-pERK1/2, anti-ERK1/2 and 
anti-actin antibodies. Bands Intensity was measured by ImageQuant analysis. Asterisk, 
fold value is expressed relative to the reference point, arbitrarily set to 1. 
 T11hT (B) or U2OS cells (C) were transfected with a siRNA directed against TBP-1 
or Luciferase. Whole extracts were probed with antibodies against Phospho-Akt 
Ser473, Akt and actin.  
 
37 
 
As shown in Figure 12, transient re-expression of TBP-1 in the faster 
proliferating T1 clone dramatically reduces its proliferation rate, both in 
presence (A) and absence (B) of serum.  
Western Blot of whole cell extracts and specific immunodetection with anti-
TBP1 and anti-pAkt antibodies clearly shows that the overexpression of TBP-1 
in the T1 clone determines a strong reduction in the Akt activation (Figure 12A 
and B, lower panels). Interestingly, when the expression of exogenous TBP-1 
was reduced, after 48 hours from the transfection, cells start to proliferate faster 
(compare upper and lower panels in Figure 12A and B), strongly indicating 
that Akt activation is linked to TBP-1 intracellular levels.  
 
 
 
Figure 12  TBP-1 rescue in the T1 clone reduces the proliferation rate.  
 
A, B: Cells from the T1 clone were transfected by electroporation with empty vector 
(indicated just as T1) or TBP-1 expression plasmid (indicated as T1 + TBP-1); cells 
were then cultured either in the presence (A) or in absence (B) of serum and collected 
at the time points indicated (being T0 the time at 24 hours after transfection).  Cells 
from each time point have been counted in a Burker chamber. Values are mean + SE 
of two experiments performed in triplicate and are indicated as values relative to the 
reference point (T0).  
Lower panels: TBP-1 expression and Akt activation have been evaluated by Western 
Blot with anti-TBP-1, anti-Phospho-Akt (Ser-473), anti-Akt and anti-actin, as loading 
control, on whole protein lysates of cells collected at each time point, as indicated. 
  
38 
 
 
We confirmed that TBP-1 overexpression counteracts Akt activation also in 
another cellular context (U2OS) and in a different kind of experiment. We 
evaluated the extent of Akt activation following insulin stimulation, a well 
known inducer of Akt kinase, in condition of TBP-1 overexpression. To this 
purpose, U2OS cells were transfected with a fixed amount of pcDNA empty 
vector or increasing amounts (0.2 and 0.5 ?g) of pcDNA TBP-1 expression 
vector. 24 hours after transfection the cells were stimulated by insulin addition 
for ten minutes and cell lysates were analyzed by Western Blot.  
As shown in Figure 13, TBP-1 overexpression counteracts Akt activation by 
insulin stimulation.  
This observation further proves the existance of causal relationship between 
TBP-1 levels and Akt activation and strongly suggests that TBP-1 can act 
upstream of the Akt kinase.  
 
 
 
Figure 13 TBP-1 overexpression counteracts akt activation. 
 
U2OS cells were transfected with 0.2 and 0.5 ?g of the pcDNA TBP-1 expression 
vector. 24 hours after transfection, cells were serum starved for 4 hours and then 
treated with 10 ng/ml insulin for 10 minutes. Extracts were analyzed by Western blot 
and immunorevealed with anti TBP-1, anti pAkt, anti-Akt/PKB and anti-actin 
antibodies. 
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4.4 TBP-1 and AKT are linked in a reciprocal regulatory loop. 
 
We next decided to investigate whether TBP-1 protein levels are regulated by 
activation or inhibition of PI3K/Akt pathway.  
To this purpose either T11hT or U2OS cells were stimulated by insulin 
addition for the indicated time periods. Protein lysates were prepared and 
analyzed by Western Blots with anti-TBP-1 and anti-pAkt antibodies. 
Strikingly, insulin treatment results in a rapid drop of TBP-1 intracellular 
levels: TBP-1 levels are reduced of around two times in 5 minutes and remain 
low up to 40 minutes with a kinetic that mirrors that of activation of Akt/PKB 
(Figure 14A and B). On the other hand, other proteasome subunits (Rpt-6 and 
C8) protein levels remain stable or, at least, slightly increased, following 
insulin treatment. These experiments suggest that TBP-1 responds to acute 
insulin stimulation with a decrease of its intracellular levels in two different 
cellular contexts. Conversely, when we inhibited the PI3K/Akt pathway 
(Wortmannin and LY294002) to analyze the effects on TBP-1 protein levels, 
we observed an increase in TBP-1 endogenous levels in both U2OS and T11hT 
cells. This suggest that TBP-1 is, indeed, either directly or indirectly regulated 
by PI3K/Akt pathway (Figure 15A,B).  
 
 
 
Figure 14 TBP-1 levels decrease following insulin treatment.  
U2OS (A) and T11hT (B) cells were serum starved for 4 hours and then treated with 
10 ng/ml of insulin for the time indicated. Cellular lysates were analyzed by Western 
Blot and revealed with anti pAkt, anti TBP-1, anti PSMC5 and anti C8 antibodies. 
Anti actin was used as loading control. TBP-1 bands intensity was measured by 
ImageQuant analysis on two different expositions to assure the linearity of each 
acquisition, each normalised for the respective actin values. Asterisk, fold value is 
expressed relative to the reference point, (i.e. TBP-1 levels in starved cells) arbitrarily 
set to 1.  
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Figure 15  PI3K inhibitors upregulate TBP-1 levels.  
 
U2OS (A) or T11hT (B) cells were treated, 24 hrs after plating, either with DMSO (/) 
or with 200nM Wortmannin or 50 µM LY294002 for the times indicated. Cells were 
then lysed and Western Blot analysis was performed by using specific antibodies 
against phospho-Akt (Ser-473), anti-Akt, anti-TBP-1, anti-C8 and anti-Rpt-6. TBP-1 
bands intensity was calculated as in figure 14.  
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To verify the direct involvement of the Akt kinase in controlling TBP-1 levels, 
we analyzed the effects of a Constitutively Active mutant of Akt (CA-Akt) (see 
Materials and Methods) on TBP-1 intracellular levels.  
U2OS cells were transfected with increasing amounts of CA-Akt expressing 
vector (kindly provided by Prof. G. Condorelli) and cell lysates were analyzed 
by Western Blot.  
As indicated in Figure 16, overexpression of CA-Akt was accompanied by a 
reduction of endogenous TBP-1 levels, while other proteasome subunits (Rpt1, 
Rpt6) protein levels remain unchanged suggesting that this effect is specific to 
TBP-1. Levels of expression of  pGSK3ȕ, a direct downstream target of Akt, 
resulted consistent with the observed Akt activation. 
Taken together these data strongly indicate the existence of a reciprocal 
regulatory loop in which Akt and TBP-1 balance and control each other.  
We GLGQ¶W REVHUYH any physical interaction between the two proteins, 
suggesting the existence of mediator(s) of these effects. 
 
 
 
Figure 16 CA-AKT overexpression reduces TBP-1 levels. 
 
U2OS cells were transfected either with empty vector (lane 1) or increasing amounts 
(0,2; 0,5; 1µg) of the constitutive active mutant of the Akt kinase (CA-Akt) expression 
plasmid. After 24 hrs cells were lysed and whole cell lysates probed with anti-
phospho-Akt (Ser-473), anti-Akt, anti-TBP-1, anti-Rpt-1, anti-Rpt-6, and anti-
phospho-*6.ȕ 
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As a first attempt, we wondered if PTEN that is among the main regulators of 
Akt activation could be involved in TBP-1 action on Akt activation. Infact, as 
mentioned in the introduction, PTEN inhibits phosphoinositide 3-kinase 
(PI3K)-dependent signaling dephosphorylating phosphatidylinositol 3,4,5-
triphosphate (PIP3) (Maehama et al. 1998). We repeated the same kind of 
experiment shown in Figure 13 in U2OS cells either treated with a PTEN 
specific siRNA or with a luciferase siRNA and evaluated the extent of Akt 
activation following insulin stimulation, in conditions of TBP-1 
overexpression.  U2OS cells were co-transfected with a fixed amount of 
pcDNA empty vector or increasing amounts (0.2 and 0.5 ?g ) of pcDNA TBP-1 
vector either with a PTEN siRNA or with a luciferase siRNA. 24 hours after 
transfection, cells were stimulated by insulin addition at the concentration of 10 
ng/ml for five minutes and cell lysates were analyzed by Western Blot. 
Interestingly, as shown in Figure 17, PTEN silencing inhibits the effect of 
TBP-1 overexpression on Akt activation.  
This preliminary result suggests the involvement of PTEN although the 
mechanism by which TBP-1 prevents Akt/PKB activation will be the subject of 
further studies. 
 
 
 
 
Figure 17 TBP-1 overexpression does not interfere with AKT activation in 
the absence of PTEN. 
 
U2OS cells were transfected with the pcDNA TBP-1 expression vector either with 
10nM siRNA PTEN or with a luciferase siRNA. 24 hours after transfection, cells were 
serum starved for 4 hours and treated with 10 ng/ml insulin for 10 minutes. Extracts 
were analyzed by Western Blot and immunorevealed with anti-TBP-1, anti-pAkt, anti 
PKB/Akt and anti-PTEN antibodies. 
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We then wondered which could be the mediator of Akt/PKB action on TBP-1 
intracellular levels. As mentioned in the introduction, among the known 
Akt/PKB effectors, is the MDM2 (Mouse Double Minute) protein that 
increases its activity following phosphorylation by Akt/PKB (Mayo and 
Donner 2001; Zhou et al. 2001a).  
We asked whether MDM2 mediates the functional relationship between TBP-1 
and Akt/PKB. We stimulated U2OS osteosarcoma cells, that were previously 
either treated with a MDM2 specific siRNA or, as control, with a luciferase 
siRNA, by insulin treatment for the indicated time periods and analyzed protein 
lysates by Western Blots with anti-TBP-1, anti-pAkt and MDM2 antibodies. 
Interestingly, MDM2 silencing prevented the reduction of TBP-1 intracellular 
levels following insulin treatment, suggesting that MDM2 could be the 
mediator of Akt/PKB action on TBP-1 intracellular levels (Figure 18).  
 
 
 
Figure 18 Activation of PI3K/AKT pathway does not interfere with TBP-1 
intracellular levels in the absence of MDM2. 
 
U2OS cells were transfected with a siRNA directed against MDM2 or Luciferase, as 
control, at the final concentration of 10nM. After 24 hrs, cells were starved for 4 hrs 
and then treated with 10 ng/ml insulin for the times indicated. Cells were then lyzed 
and Western Blot analysis was performed by using specific antibodies against 
Phospho-Akt Ser473, TBP-1, MDM2, Akt, and actin.  
 
44 
 
4.5 TBP-1 is a downstream target of MDM2  
 
To further analyze the role of MDM2 on TBP-1 protein levels, we transfected 
U2OS cells either with pcDNATBP-1 and increasing amounts of 
pCMVMDM2 expression plasmid. Cell lysate were analyzed by Western Blot 
with antibodies against TBP-1, MDM2 and actin. As shown in Figure 19, 
MDM2 overexpression in U2OS cells reduces TBP-1 levels, both endogenous 
and transfected.  
The next question was whether TBP-1 and MDM2 could interact in 
coimmunoprecipitation experiments. To this purpose, U2OS cells were either 
transfected with the MDM2 expression plasmid or with the empty vector. 24 
hrs after transfection, cell extracts were prepared, subjected either to 
immunoprecipitation with anti-TBP-1 (Fig. 20A) or anti-MDM2 (Figure 20B) 
antibodies and revealed with either anti-MDM2 or anti-TBP-1 antibodies.  
The results show that endogenous TBP-1 is a binding partner of MDM2 
(Figure 20A and B). We noted that the amount of co-immunoprecipitated 
protein (either MDM2 or TBP-1) is fewer when cells are transfected with 
MDM2, further confirming the effect of MDM2 on TBP-1.  
 
 
 
 
 
Figure 19 MDM2 overexpression reduces TBP-1 levels, both endogenous 
and transfected. 
 
U2OS cells were transfected with a fixed amount of TBP-1 expression plasmid and 
increasing amounts of MDM2 expression plasmid. After 24 hrs, cells were lysed and 
whole cell extracts probed with anti-TBP-1, anti-MDM2, and anti-actin, for loading 
control. 
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Figure 20 A,B. TBP-1 interacts with MDM2. 
A: U2OS cells were either transfected (lanes +) or untransfected (lanes 2) with the 
MDM2 expression plasmid. 24 hrs after transfection cell extract was subjected either 
to immunoprecipitation with anti-TBP-1 antibody where indicated or, with anti-GFP 
antibody as negative control. Cell extracts were also incubated with protein A-agarose 
as control, where indicated. Immunoprecipitated extracts were analyzed by Western 
Blot with anti-MDM2 or anti-TBP-1 antibody. Aliquots of cell extracts were analyzed 
by Western Blot before immunoprecipitation (input). B: U2OS cells were either 
transfected (lanes +) or untransfected (lanes 2) with the MDM2 expression plasmid. 
24 hrs after transfection cell extract was prepared and subjected either to 
immunoprecipitation with anti-MDM2 antibody where indicated or, with anti-Flag 
antibody as negative control. Cell extracts were also incubated with protein A-agarose 
as control, where indicated. Immunoprecipitated extracts were analyzed by Western 
Blot with anti-MDM2 or anti-TBP-1 antibody. Aliquots of cell extracts were analyzed 
by Western Blot before immunoprecpitation (input). 
46 
 
Since the observed effect occurs both on the endogenous and on the exogenous 
protein, it is likely that MDM2 acts on TBP-1 at the post-transcriptional level. 
Consistently, we observed that treatment of U2OS cells with the proteasome 
inhibitor MG132 counteracts the MDM2 effect on TBP-1intracellular levels, 
indicating the proteasome as the final effector of the MDM2 action on TBP-1 
(Figure 21). 
As mentioned before, MDM2 is a direct downstream target of Akt/PKB kinase. 
In fact it has been shown that Akt phosphorylates MDM2 at Serine 166, 186 
and 188 (Zhou et al. 2001; Mayo et al. 2001; Feng et al. 2004). 
We thus asked if point mutations in MDM2 that render it less responsive to 
Akt/PKB stimulation (Zhou et al. 2001; Ogawara et al. 2002; Feng et al. 2004; 
Mayo et al. 2001) reduces, as well, its ability to downregulate TBP-1 levels. 
To test this hypothesis we generated the MDM2S166A and MDM2S166A/186A point 
mutants (for details see Materials and Methods) through site directed 
mutagenesis and analyzed the effect of this mutant on TBP-1 intracellular 
levels.  
U2OS cells were transfected either with pcDNATBP-1 and increasing amount 
of pCMVMDM2S166A or pCMVMDM2S166A/186A expression plasmids.  
Cell lysate were analyzed by Western Blot with antibodies against TBP-1 and 
MDM2. As shown in Figure 22 (A,B), MDM2 mutants appear almost unable to 
mediate TBP-1 degradation, indicating that only a functionally Akt-responsive 
MDM2 molecule, could regulate TBP-1 levels.  
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Figure 21. MDM2 downregulates TBP-1 protein levels acting in a 
proteasome dependent manner.  
 
U2OS cells were transfected with TBP-1 expression plasmid and increasing amounts 
of MDM2 expression plasmid. After 24 hrs cells were treated either with DMSO (first 
four lanes) or with 10 µM MG132 where indicated. Cell extracts were analyzed by 
Western Blot with anti-Xpress (to reveal transfected TBP-1), anti-MDM2, and anti-
actin, for control. 
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Figure 22. MDM2S166A and MDM2S166A/186A mutants are unable to 
downregulate TBP-1 protein levels. 
 
A, B: U2OS cells were transfected with TBP-1 expression plasmid and increasing 
amounts of either MDM2wt, MDM2S166A or MDM2S166A/S186A expression plasmids. 
After 24 hrs cells were lysed and whole cell extracts were analyzed by Western Blot 
with anti-Xpress (to reveal transfected TBP-1), anti-MDM2, and anti-actin, for 
control.  
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We thus asked if phosphrylation mutant of MDM2 (MDM2S166A/186A), that is 
unable to downregulate TBP-1 protein levels, is still able to bind TBP-1.  
To this purpose, MEF (Murine Emrionic Fibroblast) p53-/- MDM2-/- cells 
were either untransfected or transfected with pcDNATBP-1 in combination 
with pCMVMDM2 or pCMVMDM2S166A/186A expression plasmids.  
Cellular extracts were subjected to immunoprecipitation with anti-X-press 
antibody, run on a SDS-Page, blotted and incubated with anti-X-press (to 
reveal transfected TBP-1) and anti-MDM2 antibodies.  
The result shows that MDM2 phosphrylation mutant (MDM2S166A/186A) is still 
able to bind TBP-1 (Figure 23). 
It is known that MDM2 has multifaceted roles in protein degradation.  
The well described role of MDM2 is that of an E3-ubiquitin ligase which 
mediates the ubiquitination and proteasome degradation of the p53 tumor 
suppressor protein (Honda et al. 1997; Momand et al. 2000). 
Furthermore, MDM2 has been shown to mediate proteasome-dependent but 
ubiquitin-independent degradation of p21Waf1/Cip1 (Jin et al. 2003) and of 
Retinoblastoma Protein (Sdek et al. 2005) through direct binding with the C8 
subunit of the 20S proteasome.  
Since the effect of MDM2 on TBP-1 levels occurs both on the endogenous and 
on the transfected protein, it is likely that MDM2 acts on TBP-1 at the post-
transcriptional level. We asked whether this could occur through the 
ubiquitination domain of MDM2 (ring finger).  
For this reason we analyzed the effect of the MDM21±441 deletion mutant (Jin et 
al. 2003), that lacks the ring finger domain, on TBP-1 intracellular levels.  
The results indicated that MDM21±441 deletion mutant mediates the 
downregulation of TBP-1 intracellular levels, suggesting that ubiquitine ligase 
activity of MDM2 is not necessary (Figure 24). 
It has been reported that MDM2 can act as a molecular cargo and shuttle p63 
protein to the cytoplasm mediating its interaction with proteins specifically 
involved in its turnover (Galli et al. 2010).  
Morover, it has been shown that MDM2 phosphorylation by Akt determines 
shuttling of MDM2 from the cytoplasm to the nucleus (Mayo et al. 2001; Zhou 
et al. 2001).  
Accordingly, we noticed that MDM2S166A and MDM2S166A/186A phosphorylation 
mutants are unable to mediate TBP-1 degradation suggesting that cellular 
localization plays a role in this effect.  
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Figure 23. The MDM2S166A/186A phosphrylation mutant is still able to bind 
TBP-1.  
 
MEF p53-/- MDM2-/-  cells were either transfected (lanes +) or untransfected (lanes -) 
with the pcDNATBP-1, pCMVMDM2 or pCMVMDM2 S166A/186A expression plasmids. 
24 hrs after transfection cell extract was prepared and subjected to 
immunoprecipitation with anti-X-press antibody where indicated. Cell extracts were 
also incubated with protein A-agarose as control, where indicated. 
Immunoprecipitated extracts were analyzed by Western Blot with anti-MDM2 or anti-
x-press (to reveal transfected TBP-1) antibodies. Aliquots of cell extracts were 
analyzed by Western Blot before immunoprecipitation (Input). 
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Figure 24. The downregulative effect of MDM2 on TBP-1 does not require 
the ubiquitine ligase activity of MDM2. 
 
U2OS cells were transfected with 0.1 ?g of the TBP-1 plasmid alone or together with 
increasing amounts of the MDM2 plasmids indicated. Cellular extracts were resolved 
by SDS PAGE and analyzed by Western Blot with anti MDM2 and anti-TBP-1 
antibodies. Actin was checked as loading control. 
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We thus analyzed the effect of the MDM2 deletion mutant (MDM2ǻ150±230) on 
TBP-1 intracellular levels. This mutant lacks all the Akt target sites in MDM2 
and it was described to be unable to shuttle between the nucleus and the 
cytoplasm, displaying a predominant cytoplasmic localization, because lacks 
nuclear localization and nuclear export signals (Jin et al. 2003).  
U2OS cells were transfected either with pcDNATBP-1 and increasing amounts 
of pCMVMDM2ǻ150±230 expression plasmids. As shown in Figure 25, this 
mutant appears unable to act on TBP-1 levels, suggesting that probably the 
MDM2 action on TBP-1 intracellular levels requires its nuclear localization 
that is described to occur following phosphorylation by Akt. Overall these data 
provide clear evidence that TBP-1 is a downstream target of the Akt/PKB-
MDM2 axis, even though the molecular mechanisms through which MDM2 
acts on TBP-1 intracellular levels remain to be understood.  
 
 
 
 
Figure 25. The MDM2ǻ150±230 is unable to downregulate TBP-1 protein 
levels.  
U2OS cells were transfected with 0.1 ȝg of the TBP-1 plasmid alone or together with 
increasing amounts of the MDM2 plasmids indicated. Cellular extracts were resolved 
by SDS PAGE and analyzed by Western Blot with anti MDM2 and anti-TBP-1 
antibodies. Actin was checked as loading control. 
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4.6 Discussion 
 
In this work we provide evidences that stable reduction of TBP-1 expression 
levels in primary human fibroblasts immortalized by h-TERT, affects cell 
proliferation and resistance to serum-deprivation induced apoptosis. 
Furthermore, TBP-1-silenced cells appear capable to survive in absence of 
serum much better than control as judged by a MTS assay.  
TBP-1 reduction causes an increase in the activation status of the Akt/PKB 
serin-threonin kinase, known to control the balance between cell survival and 
apoptosis. It has to be underlined that this can be directly ascribed to TBP-1 
depletion, rather than to clonal secondary effects, as it also occurs after 
transient silencing of TBP-1 and irrespective of the cell type. Remarkably, 
transient expression of TBP-1 in one of the silenced clones restores phospho-
Akt basal levels and drastically reduces the proliferation rate. Furthermore, 
TBP-1 overexpression in other cellular systems prevents Akt/PKB activation 
by insulin, thus confirming that TBP-1 can act upstream of Akt.  
In principle, the increase of Akt/PKB activity could account for all the changes 
induced by TBP-1 silencing (i.e. proliferation, cell viability, escape from 
apoptosis, migration capabilities).  
Activation of the Akt/PKB pathway plays a central role in tumorigenesis. 
Indeed, Akt is overexpressed in many different tumour cell types, with a 
burgeoning list of substrates implicated in oncogenesis (Datta et al. 1997). 
Cellular transformation is a stepwise process, and several successive genetic or 
epigenetic changes are required for the development of a neoplastic phenotype. 
It seemed plausible to hypothyze that, by acting on Akt/PKB, down-
modulation of TBP-1 intracellular levels might contribute to the acquisition of 
a transformed phenotype. In this context, we wondered whether TBP-1 
silenced clones could have acquired the ability to grow in soft agar. However, 
we were unable to show any growth of both the T1 and T10C clones, 
suggesting that other genetic lesions are needed in order to acquire a full 
transformed phenotype (Fabio Tolino, personal communication). An intriguing 
SRVVLELOLW\WRH[SORUHLVWKHLQWURGXFWLRQRI³NH\´FHOOXODUOHVLRQVWRFDXVHcell 
transformation in these clones. 
The mechanism by which TBP-1 prevents Akt/PKB activation remains an open 
question. Like the other AAA-ATPases of the 19S base of the proteasome, 
TBP-1 is supposed to act by conferring specificity to the proteasome (Voges et 
al. 1999). In fact, it has been shown to be directly involved in negative 
regulation of intracellular levels of HIF-1Į (Corn et al. 2003) and Fra-1 (Pakay 
et al. 2011), two transcriptional factors overexpressed in a variety of human 
cancers. Moreover, my research group has already observed that TBP-1 
stabilizes p14ARF avoiding its entrance into the proteasome and enhancing its 
oncosuppressive functions (Pollice et al. 2004; Pollice et al. 2007).  
Thus, TBP-1 appears to serve a role in the control of cell proliferation either 
through the increase of degradation of two oncogenes or in the stabilization of 
an oncosuppressor. On the other hand, an increase in the proliferation rate is 
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frequently associated to an increase of proteasome levels needed to guarantee 
high metabolic activity. Proteasome subunits often appear to be the target of 
cancer-related de-regulation and are involved in tumour progression. Despite 
evidences that dysregulation of the catalytic processes mediated by the 
proteasome system is associated with tumorigenesis and tumor progression, the 
relationship between proteasome expression and cancer progression is still 
poorly understood. Abnormal expression levels of proteasome subunits have 
been described in many tumour cells and proteasome plasma levels appear 
elevated in neoplastic patients underlying the involvement of the proteasome in 
cancer developement (Lavabre-Bertrand et al. 2001; Bazzaro et al. 2006). On 
the other hand, proteasomal inhibition causes increased cell death in lymphoma 
cell lines when compared with normal lymphoblasts (Soligo et al. 2001). 
Moreover, it has been reported that gankyrin, an oncogene overexpressed in 
human hepatocellular carcinoma, interferes with the proteasome activity.  
In particular, gankyrin interacts with the TBP-7 subunit increasing the 
degradation of the pRB transcription factor and subsequent increase of the 
cellular proliferation (Higashitsuji et al., 2000). Another evidence suggests that 
the HEC protein (Highly Expressed in Cancer) specifically interacts with the 
S7 ATPase and would be able to inhibit its ATPase activity, preventing the 
degradation of the A and B cyclin, necessary for the progression of the cell 
cycle from the G2phase to the M phase (Chen et al. 1997).  
However, various observations suggest that TBP-1 may act, as well, in a 
proteasome independent manner (Gonzales et al. 2002; Lassot et al. 2007; 
Pollice et al. 2004; Pollice et al. 2007; Satoh et al. 2009). Indeed, the 
proteasome seems very unlikely involved in the modulation of the Akt/PKB 
activity by TBP-1, as TBP-1 seems not to act on Akt intracellular levels. 
Moreover, in TBP-1 silenced clones, both proteasome composition and activity 
remain unaffected. Infact, the level of expression of other protesaome subunits 
do not change , as well as proteasome activity measured by an Elisa assay 
(Fabio Tolino, personal communication). 
Intriguingly, our results reveal the existence of a reciprocal regulatory 
loop where Akt/PKB activation leads to TBP-1 reduction and, in turn, TBP-1 
overexpression prevents Akt/PKB activation. In fact, insulin treatment of 
T11hT or U2OS cells results in a downregulation of TBP-1 intracellular levels, 
while inhibition of the PI3K/Akt pathway by Wortmannin determines an 
increase in TBP-1 endogenous levels. Accordingly, the transient 
overexpression of increasing amounts of a constitutively active mutant of the 
Akt kinase (CA-Akt) in U2OS cells determines a reduction of TBP-1 
endogenous levels.  
In search of the molecular mechanisms through which TBP-1 and AKT are 
linked each other, we hypothesized the existence of mediators of these effects 
as the two proteins appear not to interact in coimmunoprecipitation 
experiments. Our preliminar results suggest that the mechanism by which 
TBP1 prevents Akt/PKB activation could require the involvement of the PTEN 
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phosphatase, one of the main negative regulators of Akt/PKB activation 
although this will be the subject of further studies.   
On the other hand, we demonstrated that the PI3K/Akt signaling effect on 
TBP-1 is prevented in cells in which MDM2 is silenced. We thus proposed the 
MDM2 protein, one of the main direct targets of Akt/PKB activation (Zhou et 
al. 2001; Ogawara et al. 2002; Feng et al. 2004; Mayo et al. 2001), as mediator 
of the PI3K/Akt signaling on TBP-1. The data show that MDM2 can bind to 
TBP-1 and its overexpression causes a reduction of TBP-1 intracellular levels. 
Moreover, the MDM2S166A and the MDM2S166A/S186A phosphorylation mutants, 
lacking Akt responsive sites, are unable to act on TBP-1 protein levels 
although are still able to bind TBP-1, likely placing TBP-1 downstream of the 
Akt/PKB-MDM2 axis.  
It is known that MDM2 has multifaceted roles in protein degradation. In fact, 
aside its well-described role as E3-ubiquitin ligase, under appropriate stimuli, 
MDM2 can shuttle p63 to the cytoplasm mediating its interaction with proteins 
specifically involved in its turnover (Galli et al. 2010). Furthermore, MDM2 
has been shown to mediate proteasome-dependent but ubiquitin-independent 
degradation of p21Waf1/Cip1 (Jin et al. 2003) and of Retinoblastoma Protein 
(Sdek et al. 2005) through direct binding with the C8 subunit of the 20S 
proteasome. On the other hand, it has very recently been reported that MDM2 
interacts with components of the 19S proteasome in a ubiquitylation 
independent manner (Kulikov et al. 2010) claiming a wider view of its 
mechanism of action. Interestingly, the MDM2ǻ150±230 mutant that lacks all the 
Akt target sites in MDM2 and it was described to be unable to shuttle between 
the nucleus and the cytoplasm, displaying a predominant cytoplasmic 
localization (Jin et al. 2003), is not able to downregulates TBP-1 levels.  
This could imply that the MDM2 action on TBP-1 levels requires its nuclear 
localization that, indeed, is described to occur following phosphorylation by 
Akt (Ogawara et al. 2002; Mayo et al. 2001). Moreover, the fact that the 
MDM21±441 deletion mutant, that lacks the ring finger domain, is still able to 
act on TBP-1, indicates that MDM2 is not acting on TBP-1 levels through its 
ubiquitination activity, supporting the possibility that it rather acts as a 
molecular cargo and should plausibly act in concert with other pAkt effector 
molecule(s) needed to direct TBP-1 for degradation.  
Altogether this data provide further insights on the proposed antiproliferative 
role of TBP-1 (Park et al. 1999; Pollice et al.  2004; 2007) indicating the 
involvement of the Akt/PKB kinase. It is possible that, under standard growing 
conditions, TBP-1 contributes to balance Akt/PKB up-regulation; whilst, under 
growth factor acute stimulation, activation of the Akt/PKB signaling pathway 
lowers TBP-1 levels and initiate a feedback loop. 
Thus, although far from being elucidated, the relationships among the different 
pathways that TBP-1 controls (degradation of oncogenes as Fra-1 and Hif-1Į, 
stabilization of oncosuppressor as p14ARF, negative control on the activation 
of Akt/PKB), place TBP-1 at the cross road of different cellular pathways 
involved in the control of cancerogenesis. 
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5. CONCLUSIONS 
 
The data described in this thesis reveal the existence of a reciprocal regulatory 
loop in which TBP-1 and Akt balance and control each other. 
The consequence of this regulatory relationship could be that, under standard 
growing conditions, TBP-1 contributes to balance Akt/PKB up-regulation, 
whilst, under growth factor acute stimulation, activation of the Akt/PKB 
signaling pathway downregulates TBP-1 intracellular levels. 
  Our results provide further insights on the proposed potential 
oncosuppressive role of TBP-1 (Park et al. 1999; Pollice et al.  2004; 2007) and 
place TBP-1 at the cross road of different cellular pathways involved in the 
control of cancerogenesis. Infact, TBP-1 has already been described to controls 
degradation of oncogenes as Fra-1 and Hif-1? and stabilization of 
oncosuppressor as p14ARF. Our findings add a new point linking TBP-1 to 
Akt/PKB pathway, a main regulator of cellular signals that control balance 
between cell survival and apoptosis.  
In conclusion, we hypothyze that, by acting on Akt/PKB, down-
modulation of TBP-1 intracellular levels might contribute to the acquisition of 
a transformed phenotype, although other genetic lesions are needed in order to 
acquire a full transformed phenotype.  
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Abstract
TBP-1 /Tat-Binding Protein 1 (also named Rpt-5, S6a or PSMC3) is a multifunctional protein, originally identified as a regulator
of HIV-1-Tat mediated transcription. It is an AAA-ATPase component of the 19S regulative subunit of the proteasome and, as
other members of this protein family, fulfils different cellular functions including proteolysis and transcriptional regulation. We
and others reported that over expression of TBP-1 diminishes cell proliferation in different cellular contexts with mechanisms
yet to be defined. Accordingly, we demonstrated that TBP-1 binds to and stabilizes the p14ARF oncosuppressor increasing its
anti-oncogenic functions. However, TBP-1 restrains cell proliferation also in the absence of ARF, raising the question of what
are the molecular pathways involved. Herein we demonstrate that stable knock-down of TBP-1 in human immortalized
fibroblasts increases cell proliferation, migration and resistance to apoptosis induced by serum deprivation. We observe that
TBP-1 silencing causes activation of the Akt/PKB kinase and that in turn TBP-1, itself, is a downstream target of Akt/PKB.
Moreover, MDM2, a known Akt target, plays a major role in this regulation. Altogether, our data suggest the existence of a
negative feedback loop involving Akt/PKB that might act as a sensor to modulate TBP-1 levels in proliferating cells.
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Introduction
TBP1/Tat-Binding Protein 1 (also named Rpt-5, S6a or
PSMC3) is a member of a large highly conserved gene family of
ATPases (ATPAses Associated to a variety of cellular Activities)
whose key feature is a highly conserved module of 230 aa
consisting of an ATPase and a DNA/RNA helicase motif. This
protein family fulfils a large diversity of cellular functions including
cell cycle regulation, gene expression, vesicle mediated transport,
peroxisome assembly and proteasome function [1]. Indeed, as
other members of the family, TBP-1 is associated with the 19S
regulatory subunit of the proteasome, the chief site of protein
destruction in eukaryotic cells [2]. The last 10 years have
highlighted the essential role of proteolysis in governing cell
physiology. Protein breakdown is required not only for removal of
abnormal or aged proteins, but also to control most biological
pathways through the regulated degradation of key cellular factors.
Moreover, abnormal proteasome expression levels have been
described in many tumor cells and proteasome plasma levels
appear elevated in neoplastic patients, underlying the involvement
of the proteasome in cancer development [3,4]. Consistent with
the role in protein destruction, TBP-1 has been shown to bind the
tumour suppressor VHL (Von-Hippel-Landau) gene product [5]
contributing to its E3-ubiquitin ligase function towards the Hif1-a
factor, thus acting as a bona fide tumor suppressor.
On the other hand, 19S protein components (TBP-1 among
them) behave as multifaceted proteins, being implicated in
different cellular events that do not require proteolysis like
transcriptional initiation and elongation, [6,7,8] Nucleotide
Excision Repair [9] and regulation of mitosis [10].
We and others have reported that TBP-1 may function as a
negative regulator of cell proliferation: inhibition of the oncogenic
phenotype of erb-B transformed cells was accompanied by an
increase of TBP-1 intracellular levels and, accordingly, its
overexpression in erb-B transformed cells strongly inhibited tumour
formation in athymic mice [11]; furthermore, TBP-1 overexpres-
sion in different cellular contexts diminished cell proliferation
[11,12]. Our reported results [12,13] showing that TBP-1
enhances the levels of the p14ARF oncosuppressor well fit with
TBP-1 proposed antioncogenic role [11]. On the other hand, the
observation that TBP-1 overexpression can inhibit cell prolifera-
tion also in ARF minus contexts [11,12] suggests an ARF-
independent role of TBP-1, raising the question of what molecular
pathways may be involved.
In this paper, we address the role of TBP-1 in the control of cell
proliferation. To this aim we used, as model, a primary human
fibroblast cell line immortalized by h-TERT (human telomerase)
expression where p14ARF levels are undetectable and in which we
have silenced the expression of TBP-1. Our results show that
cellular levels of TBP-1 are critical in the control of cell
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proliferation pointing to a functional relationship between TBP-1
and the Akt/PKB serine-threonine kinase, one of the major
transducers of growth signals mediating proliferative and pro-
survival effects.
Results
TBP-1 depletion determines an increase in the growth
properties
We decided to first study the effects of long term silencing of
TBP-1 in an immortalized human fibroblast cell line (T11hT). To
this purpose, by retrovirus infection, we generated stable T11hT-
derived cell clones that constitutively express a sh-RNA specifically
designed to silence TBP-1 expression (see Materials and Methods).
As shown in Figure 1A, TBP-1 is efficiently silenced in six stable
clones analyzed, with an extent of silencing ranging from 80% to
48%. To exclude that reduced expression of TBP-1 may have
altered proteasome assembly and function [14], we analyzed
intracellular levels of proteasome subunits other than TBP-1 in
three of the silenced clones (T1, T10E and T10C). In all cases we
observed that the levels of expression of three different proteasome
subunits (Rpt-6, Rpt-1 of the 19S subunit and C8 of the 20S
subunit) do not change significantly as compared to parental
T11hT (Figure 1B). Furthermore, we didn’t observe any variation
of the in vitro proteasome activity of cell extracts obtained from
TBP-1-silenced clones and parental cells on two different peptide
substrates (data not shown).
We then measured the growth rate of the T1 and T10C clones
as compared to that of the T11hT cells. Figure 2A shows that both
the TBP-1 silenced clones analysed proliferate at higher rate
respect to the parental T11hT cell line. In particular, the T1 clone,
expressing very low TBP-1 levels (see Figure 1), grows at a rate
that is roughly twice that of the parental cell line. Moreover, serum
deprivation doesn’t appreciably alter the growth rate of the
silenced clones (Figure 2B). To exclude any clonal secondary effect
due to the selection process, we also generated, by stable
transfection, T11hT cell pools either containing the sh-TBP-1
vector or the empty vector. As it is shown in Figure 2C and D,
TBP-1 silenced cells, although in a less pronounced way respect to
single clones, display the same growth profile, both in presence
and absence of serum.
The enhanced growth rate in TBP-1 silenced cells seems to
be dependent on TBP-1 silencing. In fact, transient expression
of TBP-1 in the faster proliferating T1 clone dramatically
reduces its proliferation rate, both in presence (Figure 2E) and
absence (Figure 2F) of serum; however, after 48 hrs, when the
expression of exogenous TBP-1 was greatly reduced (see
Figure 2E and F, lower panels), cells start to proliferate faster
suggesting that slow proliferating TBP-overexpressing cells
were selected against.
Consistently with the ability of TBP-1 silenced clones to
actively proliferate even in the absence of serum, the cell viability
of the T1 clone, measured after 6 hrs of serum withdrawal,
remains high. In particular, T11hT cell viability was reduced
from 60% to 10% (depending on cell density), while that of the
T1 clone is reduced only up to 60% at the lowest cell density
(Figure 3A and B). We thus investigated whether TBP-1 silencing
may increase cell resistance to serum withdrawal-induced
apoptosis. As shown in Figure 3C and D, the T1 clone behaves
more resistant to serum-deprivation, respect to the parental cells,
as assessed by the very faint amounts of both Caspase-3 and
PARP-1 cleavage. Accordingly, flow cytometry analysis indicates
that serum starvation only slightly affects the percentage of T1
cells in S phase (8% reduction), while more drastically reduces
that of the parental cell line (55% reduction) (Figure 3E).
Furthermore, the increase of the sub-G1 population (of around
1.8 fold for the T1 clone and 3,14 fold for the parental cell line) is
consistent with PARP-1 and Capase-3 cleavage data (Figure 3E
and see 3C and D).
Next, we analyzed the invading capability of the T1 clone
respect to control cells by a chemoinvasion assay in which cells
were plated on Matrigel coated filters and allowed to migrate. As
shown in Figure 4A, as compared to parental cells, T1 cells possess
a moderate but significant higher ability to migrate through
Matrigel. Interestingly, similar results are also obtained when cells
were allowed to migrate toward a generic chemoattractant as EGF
(Epidermal Growth Factor) (Figure 4B). To further prove that the
difference in invasion ability could be ascribed to the reduction of
TBP-1 protein levels and not to any clonal secondary effects,
making use of a specific siRNA, we transiently silenced TBP-1 in
parental T11hT cells. Consistently, transient silencing of TBP1 is
even more effective than stable silencing in T1 cells in inducing a
Figure 1. Characterization of TBP-1 silenced clones. A, B: Cells
stably transfected with TBP1 sh-RNA plasmid or control cells (wt T11hT,
Human Primary Fibroblasts Immortalized by hTERT) were cultured in
DMEM+10%FBS for 24 hrs. Levels of TBP-1 expression was evaluated by
Western Blot with anti-TBP-1 on whole protein lysates. B: As control,
protein levels of other proteasome components (two 19S-ATPases, Rpt-
1 and Rpt-6, and a 20S component, C8) was evaluated in the clones T1,
T10C and T10E. Bands intensity was evaluated by ImageQuant analysis
on at least two different expositions to assure the linearity of each
acquisition, each normalised for the respective actin values. Asterisk,
fold value is expressed relative to the reference point (i.e. TBP-1 levels in
T11hT cells), arbitrarily set to 1. Representative of at least four
independent experiments.
doi:10.1371/journal.pone.0022800.g001
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Figure 2. TBP-1 knockdown determines an increase in the growth properties. A, B: Cells from the T1, T10C and control cells (wt T11hT)
were cultured in DMEM either in the presence (A) or in absence (B) of 10% FBS. Cells were collected at the time points indicated and counted in a
Burker chamber. The values are the mean 6 SE of three experiments performed in triplicate. C, D: wt T11hT cells, cells from control cell pool or from
the sh-TBP-1 cell pool were cultured in DMEM either in the presence (C) or in absence (D) of 10% FBS. Cells were collected at the time points
indicated and counted in a Burker chamber. The values are the mean 6 SE of three experiments performed in triplicate. E, F: Cells from the T1 clone
were transfected by electroporation with empty vector (indicated just as T1) or TBP-1 expression plasmid (indicated as T1+TBP-1); cells were then
cultured either in the presence (E) or in absence (F) of 10%FBS and collected at the time points indicated (being T0 the time at 24 hours after
transfection). Cells from each time point have been counted in a Burker chamber. Values are mean 6 SE of two experiments performed in triplicate
and are indicated as values relative to the reference point (T0). E, F lower panels: TBP-1 expression and Akt activation have been evaluated by
Western Blot with anti-TBP-1, anti-Phospho-Akt Ser473, anti-Akt and anti-actin, as loading control, on whole protein lysates of cells collected at each
time point, as indicated.
doi:10.1371/journal.pone.0022800.g002
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Figure 3. TBP-1 knockdown reduces sensitivity to serum starvation. A, B: Cells from the T1 clone and control cells (wt T11hT) were plated at
different cell densities as indicated, either in the presence or absence of 10% FBS. After six hrs from plating, cell viability was measured by MTS assay.
In the histograms, cell viability is expressed as relative to controls, arbitrarily set to 100 (%). The values are the mean 6 SE of three experiments
performed in quintuplicate. C, D: 1.86105 cells/35 mm plates from the T1 clone and control cells (wt T11hT) were grown for 24 hrs, in the presence
or absence of 10% FBS. Apoptosis was checked by detection of Caspase-3 (C) and PARP-1 (D) cleavage in Western Blot. Detection with anti-actin was
included for control of equal loading. Bands Intensity was measured by ImageQuant analysis on at least two different expositions to assure the
linearity of each acquisition. Representative of at least four independent experiments. E: T11hT and T1 cells were counted and seeded at 26105cells/
TBP-1 and Akt in the Control of Cell Proliferation
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e22800
high per cent of migrating cells (Figure 4C). Thus, the difference in
Matrigel invasion was likely due to an increased invading
capability of TBP1 silenced cells, as also suggested by the fact
that we don’t observe any difference both in the expression and
activation status of the EGF receptor (not shown).
Taken together these data show that TBP-1 sensitizes cells to
apoptosis induced by serum withdrawal and interferes with cell
growth and migration.
TBP-1 inhibits Akt/PKB activation
The observation that TBP-1 depletion allows cells to grow in a
serum-independent manner, prompted us to ask whether TBP-1
expression levels may control, in some way, the activity of the Akt/
PKB serine-threonine kinase, one of the major transducers of
growth signals, critical for cell proliferation and apoptosis. We thus
evaluated the levels of phospho-Akt in our TBP-1 depleted clones,
under actively growth conditions (i.e. in the presence of serum). As
35 mm plate. At 24 hrs cells were collected and treated for analysis of cellular DNA content by flow cytometry. Percentages of cells in the SubG1, G0–
G1, S and G2–M phases were quantified with Summit 4.1 software. Representative of three different experiments. The numerical ratios reported on
the right highlight the different behaviour of T1 cells when grown in absence or presence of serum. Table 1 provides the mean values (and standard
deviations in parentheses) relative to this analysis.
doi:10.1371/journal.pone.0022800.g003
Figure 4. Silencing of TBP-1 determines an increase of the invading capability. A: Cells from the T1 clone or control cells (wt T11hT) were
plated in Boyden chambers and allowed to migrate on filters coated with Matrigel. The values are the mean 6 SE of three experiments performed in
triplicate. (*) p = 0.046 as determined by the Student’s t test. B: Cells from the T1 clone or control cells (wt T11hT) were plated in Boyden chambers
and allowed to migrate toward EGF on Matrigel filters. 100% values represent cell migration in the absence of chemoattractants. The values are the
mean 6 SE of three experiments performed in triplicate. (*) p = 0.027 as determined by the Student’s t test. C: Cells transiently transfected with TBP1
si-RNA or with the control si-RNA (si-Luc) were plated in Boyden chambers and allowed to migrate toward EGF on filters coated with Matrigel. 100%
values represent cell migration in the absence of chemoattractants. The values are the mean6SE of three experiments performed in triplicate. (*)
p = 0.016 as determined by the Student’s t test.
doi:10.1371/journal.pone.0022800.g004
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shown in Figure 5A, pAkt/PKB levels are inversely correlated to
the extent of silencing of TBP-1, being the lowest in the parental
T11hT and the highest in the T1 clone. Consistently, we observed
an increase in the extent of phosphorylation of GSK3b, a well
characterized Akt/PKB direct target. TBP-1 reduction appears to
specifically affect Akt activation but not that of other important
transducers of growth signals, like ERK1/2. Furthermore, in
agreement with the observed higher proliferation rate of the
clones, we observed a reduction of phospho-cyclin D1 protein
levels (data not shown). Both in parental cells and in TBP-1
silenced clones, Akt activation appears to be dependent on the
upstream phosphatidylinositol 3-kinase activity (PI3K) as evi-
denced by Wortmannin and LY294002 treatment that block PI3K
activity (Figure 5B).
Importantly, we could reproduce, in T11hT cells, the same
effect after transient reduction of TBP-1 levels by siRNA: silencing
of TBP-1 was accompanied by a concomitant increase in the
steady-state level of pAkt, suggesting the existence of a causal
relationship between TBP-1 intracellular levels and Akt activation
(Figure 5C). This effect was not cell-specific since we could
reproduce it in the U2OS osteosarcoma-derived cells (Figure 5D).
Further, we set up a rescue experiment in which we re-
established high TBP-1 levels in the T1 clone by transient
overexpression. In these conditions we observed a strong reduction
of pAkt levels (Figure 5E and see also Figure 2E, F). Consistently,
insulin-mediated activation of Akt in a different cellular context
(U2OS cells) is counteracted by TBP-1 overexpression (Figure 5F).
Altogether these data suggest that TBP-1 levels modulate the
extent of Akt/PKB activation.
TBP-1 is a downstream target of Akt activation
The new insights into the role of TBP-1 in the control of cell
growth prompted us to investigate whether TBP-1 protein levels
are sensitive to acute growth factors stimulation. We thus
stimulated either T11hT or U2OS osteosarcoma cells by insulin
treatment for the indicated time periods and analyzed protein
lysates by Western Blots with anti-TBP-1 antibodies. Figure 6A
clearly shows that insulin treatment results in a rapid, transient
drop of TBP-1 intracellular levels; indeed, TBP-1 levels are
reduced of around two times in 5 min and remain low up to
40 minutes with a kinetic that mirrors that of the activation of
Akt/PKB (Figure 6A, left panel). On the other hand, other
proteasome subunits (Rpt-6 and C8) protein levels remain almost
stable or, at least, slightly increased, following insulin treatment
(Figure 6A). To test the effects of inhibition of the PI3K/Akt
pathway on TBP-1 protein levels, U2OS cells or T11hT cells were
treated for the indicated time periods with PI3K inhibitors and
protein lysates analyzed by Western Blots. As shown in Figure 6B,
inhibition of the PI3K/Akt pathway determines a slight though
reproducible increase in TBP-1 endogenous levels, suggesting that
they are either directly or indirectly regulated by PI3K activity.
Again, in these conditions, other proteasome subunits (Rpt-6 and
C8) protein levels remain stable (Figure 6B, left panel). To further
confirm these observations, we transiently transfected increasing
amounts of a constitutively active mutant of the Akt kinase (CA-
Akt) in U2OS cells. Overexpression of CA-Akt was accom-
panied by a reduction of endogenous TBP-1 levels, while other
proteasome subunits protein levels remain unchanged (Figure 6C).
Taken together, these data strongly indicate that TBP-1 protein
levels are modulated by the Akt/PKB activity.
On the other hand, by immunoprecipitation experiments we
were unable to observe any physical interaction between TBP-1
and Akt/PKB (data not shown), suggesting that TBP-1 levels are
indirectly modulated by Akt activation. We thus wondered which
could be the mediator of Akt/PKB action on TBP-1.
Among the known Akt/PKB effector is the MDM2 protein that,
following phosphorylation by Akt/PKB, increases its activity
[15,16,17]. We thus determined whether MDM2 mediates the
functional relationship between TBP-1 and Akt/PKB. In order to
obtain Akt activation, we treated with insulin U2OS cells that were
previously either treated with a MDM2 specific siRNA or, as
control, with a luciferase siRNA (Figure 6D). Interestingly, MDM2
silencing prevented the reduction of TBP-1 intracellular levels
following treatment with insulin, although has no effects on TBP-1
basal levels. Consistently, the increase in TBP-1 levels following
treatment with PI3K inhibitors, is prevented in cells in which
MDM2 is silenced (Figure 6E), suggesting that, indeed, silencing of
MDM2 renders Akt activation/inactivation ineffective on TBP-1
levels. These data strongly implicate MDM2 to be needed, even
not sufficient, for TBP-1 regulation by Akt/PKB. Involvement of
MDM2 is supported by co-immunoprecipitation experiments in
U2OS cells. As shown in Figure 7A and 7B we found TBP-1 in
complex both with endogenous and with transfected MDM2.
Furthermore, we observed that overexpression of MDM2 causes a
decrease of TBP-1 intracellular levels (Figure 7A and B, see input).
We confirmed this observation transfecting U2OS cells with fixed
concentration of pcDNA-TBP-1 and increasing amounts of the
MDM2 expression plasmid (Figure 7C). Since the observed effect
occurs both on the endogenous and on the exogenous protein, it is
likely that MDM2 acts on TBP-1 at the post-transcriptional level.
Moreover, treatment of U2OS cells with the proteasome inhibitor
MG132 counteracts the MDM2 effect on TBP-1, indicating the
proteasome as the final effector of the MDM2 action on TBP-1
(Figure 7D).
We thus asked if mutations in MDM2 that render it less
responsive to Akt/PKB stimulation [15,16,17,18] reduces, as well,
its ability to downregulate TBP-1 levels. The MDM2S166A and
MDM2S166A/186A mutants appear almost unable to mediate TBP-
1 degradation (Figure 7E), indicating that only a functionally Akt-
responsive MDM2 molecule, could regulate TBP-1 levels.
Accordingly, a MDM2 deletion mutant that lacks all the Akt
target sites in MDM2 (MDM2D150–230) [19] appear unable to act
on TBP-1 levels (Figure 7F). Interestingly, a MDM2 mutant,
lacking the ring finger domain (MDM21–441), is still able to act on
TBP-1 (Figure 7F), indicating that MDM2 is not acting on TBP-1
levels through its ubiquitination activity.
Table 1. Mean values (and standard deviations in parentheses) relative to the flow cytometry analysis described in Figure 3.
T11hT
+serum
T11hT
2serum
T1
+serum
T1
2serum
Sub-G1 12,69 (+/22,35) 39,79 (+/25,02) 13,02 (+/21,8) 29,05 (+/23,12)
S 14,87 (+/21,2) 6,44 (+/20,9) 13,94 (+/21,75) 14,13 (+/22,49)
doi:10.1371/journal.pone.0022800.t001
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Figure 5. TBP-1 knockdown determines activation of the Akt/PKB kinase. A: Cells from the T1, T10C and control cells (wt T11hT) were
cultured in DMEM+10%FBS for 24 hrs. Activation of Akt/PKB was revealed by Western Blot with anti-Phospho-Akt Ser473 antibody. As control,
extracts were also probed with anti-Akt, anti-Phospho-GSK-3b/pSer219, anti-pERK1/2, anti-ERK1/2 and anti-actin antibodies. Bands Intensity was
measured by ImageQuant analysis on at least two different expositions to assure the linearity of each acquisition, each normalised for the respective
actin values. Asterisk, fold value is expressed relative to the reference point, arbitrarily set to 1. Representative of at least four independent
experiments. B: Cells from the T1 clone or control cells (wt T11hT) were plated at the cell density of 2.56105 in DMEM+10%FBS in six wells. After
24 hrs, either DMSO (/) or with Wortmannin or LY294002, where indicated, were added to the cells at the concentrations indicated and left for either
1 hour (with Wortmannin) or 159(with LY294002). Extracts were then probed in Western Blot with antibodies against Akt, Phospho-Akt Ser473 and
actin. C, D: T11hT cells (C) or U2OS cells (D) were transfected with an siRNA directed against TBP-1 or Luciferase. Extracts were probed with
antibodies against Phospho-Akt Ser473, Akt and actin. E: Cells from the T1 clone were transfected with empty vector (first lane) or increasing
amounts of TBP-1 expression plasmid. Activation of Akt/PKB was evaluated by Western Blot on whole protein lysates probed with anti-Phospho-Akt
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These data provide clear evidence that TBP-1 is a downstream
target of the Akt/PKB-MDM2 axis, even though the molecular
mechanisms through which MDM2 acts on TBP-1 remain to be
elucidated.
Discussion
Herein we report data showing that reduction of TBP-1
intracellular levels affects cell proliferation, invading capabilities
and resistance to apoptosis of human fibroblasts immortalized by
h-TERT expression. Interestingly, unlike the parental cells,
proliferation of TBP-1 silenced clones appears to be serum-
independent. Our data indicate that TBP-1 modulates the extent
of activation of the Akt/PKB kinase, a critical effector of
intracellular signaling. In fact, we demonstrate that reduction of
TBP-1 intracellular levels causes the activation of the Akt signaling
pathway. It has to be underlined that this can be directly ascribed
to TBP-1 depletion rather than to clonal secondary effects as it also
occurs after transient silencing of TBP-1 and irrespective of the cell
type. Remarkably, transient expression of TBP-1 in one of the
silenced clones restores phospho-Akt basal levels and drastically
reduces the proliferation rate. Furthermore, TBP-1 overexpression
in other cellular systems prevents Akt/PKB activation thus
confirming that TBP-1 can act upstream of Akt.
Activation of the Akt/PKB pathway plays a central role in
tumorigenesis. Indeed, Akt is overexpressed in many different
tumour cell types, with a burgeoning list of substrates implicated in
oncogenesis [20]. In principle, the increase of Akt/PKB activity
could account for all the changes induced by TBP-1 silencing (i.e.
proliferation, cell viability, escape from apoptosis, migration
capabilities) [21,22,23,24]. On the other hand, the acquisition of
a transformed phenotype is a quite complex stepwise accumulation
of genetic changes [25,26]. In this context, it seems plausible to
predict that, by acting on Akt/PKB, down-modulation of TBP-1
intracellular levels might contribute to the acquisition of a
transformed phenotype thus cooperating with other genetic
lesions. Since TBP-1 silenced clones are normal fibroblasts that
only bear h-TERT overexpression to guarantee immortalization,
an intriguing possibility to explore is the introduction of ‘‘key’’
cellular lesions to cause cell transformation in these clones.
The mechanism by which TBP-1 prevents Akt/PKB activation
remains an open question. Even though, like the other AAA-
ATPases of the 19S base of the proteasome, TBP-1 is supposed to
act by conferring specificity to the proteasome [27,28] various
observations suggest that TBP-1 may act, as well, in a proteasome
independent manner [6,7,8,12,13,29]. Indeed, the proteasome
seems very unlikely involved in the modulation of the Akt/PKB
activity by TBP-1. In fact, an increase in the proliferation rate is
frequently associated to an increase of proteasome levels needed to
guarantee high metabolic activity. Here we show that TBP-1
silenced clones don’t display a significant alteration in proteasome
composition and activity. Furthermore, unlike other proteasome
components (C8 and Rpt-6), TBP-1 responds to acute insulin
stimulation with a decrease of its intracellular levels. In a different
context, other proteasome subunits respond to growth factor
stimulation with an increase of intracellular levels [30].
It has to be underlined that we have already observed that TBP-
1 stabilizes p14ARF [12,13] avoiding ARF entrance into the
proteasome. We retain that TBP-1 could play a role in ARF
folding, rendering it a poor substrate for degradation by the 20S as
well as by the 20S/11S proteasome [31,32]. The existence of a
similar mechanism that permits to TBP-1 to increase the
intracellular levels of proteins that regulate Akt/PKB activity is
the subject of further studies.
Furthermore, our results reveal the existence of a reciprocal
regulatory loop where Akt/PKB activation leads to TBP-1
reduction and, in turn, TBP-1 overexpression prevents Akt/PKB
activation. In this scenario, the Akt/PKB kinase thus might act as
a sensor that modulates TBP-1 levels in actively duplicating cells.
On the other hand, based on the fact that the PI3K/Akt signaling
effect on TBP-1 is prevented in cells in which MDM2 is silenced,
we propose, as mediator of the PI3K/Akt signaling on TBP-1, the
MDM2 protein, one of the main direct targets of Akt/PKB
activation [15,16,17,18]. Actually, MDM2 can bind to TBP-1 and
its overexpression causes a reduction of TBP-1 intracellular levels.
Strikingly, the MDM2S166A/S186A mutant and the MDM2D150–230,
lacking Akt responsive sites, are unable to act on TBP-1 protein
levels, likely placing TBP-1 downstream of the Akt/PKB-MDM2
axis.
Even though the specific mechanism for MDM2-dependent
depression of TBP-1 levels remains to be understood, it has to be
noted that MDM2 has multifaceted roles in protein degradation.
In fact, aside its well-described role as E3-ubiquitin ligase, under
appropriate stimuli, MDM2 can shuttle p63 to the cytoplasm
mediating its interaction with proteins specifically involved in its
turnover [33]. Moreover, MDM2 has been shown to mediate
proteasome-dependent but ubiquitin-independent degradation of
p21Waf1/Cip1 [19] and of Retinoblastoma Protein [34] through
direct binding with the C8 subunit of the 20S proteasome. On the
other hand, it has very recently been reported that MDM2
interacts with components of the 19S proteasome in a ubiquityla-
tion independent manner [35] claiming a wider view of its
mechanism of action.
Interestingly, the MDM2D150–230 mutant was described to be
unable to shuttle between the nucleus and the cytoplasm,
displaying a predominant cytoplasmic localization [19]. This
could imply that the MDM2 action on TBP-1 levels requires its
nuclear localization that, indeed is described to occur following
phosphorylation by Akt [15,18].
Moreover, the fact that the MDM21–441 deletion mutant, that
lacks the ring finger domain, is still able to act on TBP-1
(Figure 7F), indicates that MDM2 is not acting on TBP-1 levels
through its ubiquitination activity, supporting the possibility that it
rather acts as a molecular cargo and should plausibly act in
concert with other pAkt effector molecule(s) needed to direct TBP-
1 for degradation.
Altogether our observations provide further insights on the
proposed antiproliferative role of TBP-1 [11,12,13], indicating the
involvement of the Akt/PKB kinase. Indeed, we could speculate
that, under standard growing conditions, TBP-1 contributes to
balance Akt/PKB up-regulation; whilst, under growth factor acute
stimulation, activation of the Akt/PKB signaling pathway lowers
TBP-1 levels and initiate a feedback loop. Further, it’s interesting
to underline that the human oncosuppressor p14ARF that is
stabilized by TBP-1 overexpression [12,13] is itself able to
antagonize the activity of Akt/PKB [36] with yet unknown
Ser473 and, as control, with anti-Akt and anti-actin. F: U2OS cells were transfected with empty vector (lanes 1–4) or TBP-1 expression plasmid (lanes 5,
6). After 24 hrs cells were starved for 4 hrs and treated with 10 ng/ml insulin for 109 where indicated. Activation of Akt/PKB was evaluated by Western
Blot on whole protein lysates probed with anti-Phospho-Akt Ser473. Extracts were also probed with anti-Akt, anti-actin and anti-Xpress (to reveal
transfected TBP-1).
doi:10.1371/journal.pone.0022800.g005
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Figure 6. TBP-1 is a downstream target of Akt activation. A: U2OS cells or T11hT cells were starved for 4 hrs and then treated with 10 ng/ml
insulin for the times indicated. Activation of Akt/PKB was evaluated by Western Blot on whole protein lysates probed with anti-Phospho-Akt Ser473
and anti-Akt. Levels of endogenous TBP-1 and of two proteasome components (C8 and Rpt-6) were analyzed where indicated. TBP-1 bands intensity
was measured by ImageQuant analysis on two different expositions to assure the linearity of each acquisition, each normalised for the respective
actin values. Asterisk, fold value is expressed relative to the reference point, (i.e. TBP-1 levels in starved cells) arbitrarily set to 1. Representative of
three independent experiments. B: U2OS cells or T11hT cells were treated, 24 hrs after plating, either with DMSO (/) or with 200 nM Wortmannin or
50 mM LY294002 for the times indicated. Cells were then lysed and Western Blot analysis was performed by using specific antibodies against
Phospho-Akt Ser473, anti-Akt, anti-TBP-1, anti-C8 and anti-Rpt-6. TBP-1 bands intensity was calculated as in A. Representative of three independent
experiments. C: U2OS cells were transfected with empty vector (lane 1) or increasing amounts of the constitutive active mutant of the Akt kinase (CA-
Akt). After 24 hrs cells were lysed and whole cell lysates probed with anti-Phospho-Akt Ser473, anti-Akt, anti-TBP-1, anti-Rpt-1, anti-Rpt-6, and anti-
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mechanism. On the other hand, other reports [37] underline an in
vivo requirement of ARF for full activation of PTEN, one of the
major negative regulators of Akt activity.
In conclusion, our data well support a role for TBP-1 in the
attenuation of Akt/PKB activity and place this protein with a key
role in the control of cell proliferation. Even though, further
studies are necessary to understand the potential cross-talks linking
TBP-1 action on p14ARF and on Akt/PKB regulation.
Materials and Methods
Cell cultures, viral infection, transfections
T11hT (human primary fibroblasts immortalized by constitutive
expression of the telomerase catalytic subunit h-TERT) human
cell line was kindly provided by dr. Eric Gilson. T1, T10C and
T10E (TBP-1 silenced clones) derived by retroviral infection of
T11hT: briefly, 36106 HEK 293-LinX packaging cells (kindly
provided by Prof. Nicola Zambrano) were transfected with
ARREST-IN (Open Biosystems, Huntsville, AL, USA) with
pSUPERIOR.shTBP-1. 24 hrs after transfection, virus containing
supernatant was filtrated through 0,45 mm cellulose acetate
syringe filter, supplemented with 5 mg/ml polybrene, and used
to infect recipient T11hT cells, previously plated at 50%
confluence. Twenty-four hours following infection, 1 mg/ml
G418 was applied to select stably infected cells. After three weeks,
23 individual single G418 resistant clones were picked up and
expanded. Six neomycin resistant colonies from 5 different plates,
were screened by Western Blot with anti-TBP-1.
Both T11hT andTBP-1 silenced clones were grown inDulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% Fetal
Bovine serum and 1 mg/ml puromycin (to maintain selection for h-
TERT). U2OS cells were grown in Dulbecco’s Modified Eagle
Medium supplemented with 10% Fetal Bovine serum.
To obtain sh-TBP-1 pool and control pool, 26106 T11hT cells
were transfected by electroporation by making use of a Microporator
MP-100 (Digital Bio Technology) either with 3 mg of pSUPER-
IOR.shTBP-1 or 3 mg of pSUPERIOR.retro.neo; twenty-four hours
following transfection, 1 mg/ml G418 was applied to select cells. After
four weeks, resistant cells were collected, expanded and analyzed.
Transfection by Lipofectamine2000 were performed as de-
scribed [12].
Transfection of the T1 clone was performed by the use of a
Microporator MP-100 (Digital Bio Technology) using either
26106 cells with 2 mg of either pcDNA empty vector or
pcDNATBP-1 (rescue of cell proliferation, Figure 2E and F) or
16106 cells with either pcDNA empty vector or pcDNATBP-1
(0.3 or 0.6 mg) (rescue of Akt activation, Figure 5 E). Cells were
then plated in DMEM+10% FBS for 24 hrs at 37uC or DMEM
without FBS at 37uC and collected for subsequent analysis.
For transient silencing experiments, the duplex siRNA oligomer
designed to target human TBP-1 is described in [12]; the duplex
siRNA oligomer targeting human MDM2 has the following
sequence: 59- AAGCCAUUGCUUUUGAAGUUA-39 and was
designed as described in [19]. siRNA were all synthesized by
MWG Biotech, Germany. Either U2OS, T11hT or T1 cells were
transfected by Hyperfect (Quiagen, GmBH, Germany) according
to the manufacturer’s instructions.
Cell growth analysis, MTS assay, Flow cytometry analysis,
Chemoinvasion assay
For cell growth analysis, T11hT parental cell line, T1, T10C
and T10E clones, or T11hT, control pool and sh-TBP-1 pool,
were plated in 100 mm dishes in presence of 10% FBS at the cell
density of 16105 cells/plate. Cells were cultured for 24, 48 and
72 hrs, collected, and counted in a Burker chamber. For growth in
the absence of serum, after 6 hrs from plating, medium was
removed and replaced with medium without serum. As above,
cells have been grown for 24, 48 and 72 hrs, collected and
counted. Each point is the result of triplicate samples.
Cell viability was evaluated using the MTS [3-(4,5-di-
methylthiazhol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium,inner salt] (Cell Titer 96AQueous assay G358
purchased from Promega) colorimetric assay. Briefly, T11hT
parental cell line or cells derived from the T1 clone were plated at
different cell densities as indicated in 96 well plates (2.56103/well,
103/well, 36102 /well) either in DMEM or in DMEM+10%FBS.
After six hrs from plating, 1:5 MTS solution was added to each
well and the cells were incubated for 309 at 37uC. Plates were read
on a Microplate Reader (BIO-TEK Instruments, Model Elx800)
at 492 nm. Survival was expressed as the percentage of viable cells
in treated samples relative to non-treated control cells. All the
experiments were repeated in quintuplicate.
For flow cytometry analysis, T11hT and T1 cells were counted
and seeded at 26105cells/35 mm plate. At 24 hours after plating
the medium was replaced and the cells treated with DMEM
containing 10% Fetal bovin serum or DMEM without serum. At
the indicated time points, cells were collected, centrifuged, washed
twice with PBS 16 and then fixed with ice-cold 70% ethanol.
Fixed cells were incubated with staining buffer solution (50 mg/ml
PI and 50 mg/ml RNase A in PBS pH 7.4) for 20 minute at room
temperature in a dark box. Stained cells were analysed in a
fluorescence-activated cytometer (DakoCytomation). Data on
DNA cell-content were acquired on 20,000 events at a rate of
150650 events/second and the percentages of cells in the SubG1,
G0–G1, S and G2–M phases were quantified with Summit v4.1
software.
Chemoinvasion assays were performed in Boyden chambers
using 8 mm pore size PVPF polycarbonate filters coated with
50 mg/ml of Matrigel. 16105 cells were plated in the upper
chamber in serum-free medium. 100 ng/ml EGF or serum free
medium was added in the lower chamber. Cells were allowed to
migrate for 4 h at 37uC, 5% CO2. To examine basal migration,
serum free medium was added to both upper and lower chamber,
and migration was allowed for 12 h at 37uC, 5% CO2, in the
absence of chemoattractants.
The cells on the lower surface of the filter were then fixed in
ethanol, stained with hematoxylin, and counted at 2006
magnification (10 random fields/filter).
Western Blotting, Immunoprecipitations, Insulin
treatments, MG132 treatment
Western Blots were performed as described [12]. Antibodies to
Akt (used in 1:1000 dilution), Phospho-Akt Ser473 (used in 1:1000
dilution), Phospho-GSK-3b/pSer21/9 (used in 1:1000 dilution),
phospho-GSK3b. D: U2OS cells were transfected with a siRNA directed against MDM2 or Luciferase, as control, at the final concentration of 10 nM.
After 24 hrs, cells were starved for 4 hrs and then treated with 10 ng/ml insulin for the times indicated. Cells were then lysed and Western Blot
analysis was performed by using specific antibodies against Phospho-Akt Ser473, TBP-1, MDM2, Akt, and actin. E: U2OS cells were transfected with a
siRNA directed against MDM2 or Luciferase, as control. After 48 hrs, either DMSO (/) or 200 nM Wortmannin was added to the cells and left for the
times indicated. Cells were then lysed and Western Blot analysis was performed by using specific antibodies against Phospho-Akt Ser473, TBP-1,
MDM2, Akt and actin.
doi:10.1371/journal.pone.0022800.g006
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Figure 7. TBP-1 is a downstream target of MDM2 activation. A: U2OS cells were either transfected (lanes +) or untransfected (lanes 2) with
the MDM2 expression plasmid. 24 hrs after transfection cell extract was prepared and subjected either to immunoprecipitation with anti-TBP-1
antibody where indicated or, with anti-GFP antibody as negative control. Cell extracts were also incubated with protein A-agarose as control, where
indicated. Immunoprecipitated extracts were analyzed by Western Blot with anti-MDM2 or anti-TBP-1 antibody. Aliquots of cell extracts were
analyzed by Western Blot before immunoprecipitation (input). B: U2OS cells were either transfected (lanes +) or untransfected (lanes 2) with the
MDM2 expression plasmid. 24 hrs after transfection cell extract was prepared and subjected either to immunoprecipitation with anti-MDM2 antibody
where indicated or, with anti-Flag antibody as negative control. Cell extracts were also incubated with protein A-agarose as control, where indicated.
Immunoprecipitated extracts were analyzed by Western Blot with anti-MDM2 or anti-TBP-1 antibody. Aliquots of cell extracts were analyzed by
Western Blot before immunoprecpitation (input). C: U2OS cells were transfected with TBP-1 expression plasmid and increasing amounts of MDM2
expression plasmid. After 24 hrs, cells were lysed and whole cell extracts probed with anti-TBP-1, anti-MDM2, and anti-actin, for loading control. D:
U2OS cells were transfected with TBP-1 expression plasmid and increasing amounts of MDM2 expression plasmid. After 24 hrs cells were treated
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Caspase-3 (1:1000) and PARP-1 (1:1000) were purchased from
Cell Signalling Technologies, Boston, MA, USA. Antibodies to
MDM2 (used in 1:500 dilution) was purchased from Calbiochem,
to Rpt-1 (PSMC2) (used in 1:6000 dilution), Rpt6 (PSMC5) (used
in 1:6000 dilution) and C8 (used in 1:6000 dilution) were
purchased from BioMol. Anti-Xpress antibody (used in 1:1000
dilution) was purchased from Invitrogen. Secondary antibodies for
Western Blot analysis (goat anti-rabbit IgG-HRP 1:3000 dilution)
were purchased from Santa Cruz Biotechnology, CA, USA.
Proteins were visualized with an enhanced chemiluminescence
detection system (Amersham ECL TM) and images were taken with
ChemiDoc XRS System (Bio-Rad Laboratories) and analysed
with the QuantityONE software.
For insulin treatment, U2OS cells were transfected by
Lipofectamine with 0.2 and 0.5 mg of the pcDNATBP-1 plasmid.
At 24 hrs after transfection, cells were starved for 4 hrs and then
treated with 10 ng/ml insulin for 109.
To analyze TBP-1 levels following insulin treatments, either
U2OS cells or T11hT cells were starved for 4 hrs and then treated
with 10 ng/ml insulin for the times indicated.
For immunoprecipitation in U2OS cells, 1.06106 cells were
seeded in 100 mm dishes and transfected with the plasmids
indicated in the figure legend. Cells were harvested 24 hours after
transfection and cell lysates were prepared as described [12]:
800 mg of whole cell extract were incubated overnight at 4uC
with anti-TBP1 (BioMol) or anti-MDM2 C18 (Santa Cruz).
Controls of immunoprecipitations were perceived with mouse
anti-GFP (Roche) or rabbit anti-Flag (Sigma). Immunocomplexes
were collected by incubation with 30 ml of protein A-agarose
(Roche Applied Science) at 4uC for 4 hrs. The beads were washed
with Co-Ip buffer (50 mM tris-HCL pH 7.5; 150 mM NaCl;
5 mM EDTA; 0,5% Np40), resuspended in 26 loading buffer
(Sigma) and loaded on a SDS-8% polyacrylamide gel.
Treatment with proteasome inhibitor was performed as follows:
U2OS cells were treated either with DMSO or 10 mMMG132 for
five hours. Cells were harvested and total extracts prepared for
subsequent analysis as described.
Constructs
pSUPERIORshTBP-1 has been obtained from pSUPERIOR.-
retro.neo (Oligoengine) by cloning into BglII-HindII sites a duplex
oligonucleotide obtained by MWG-Biotech that could give rise to
a short hairpin RNA specifically designed to silence TBP-1
expression.
Oligoseq: 59GATCCCCAACAAGACCCTGCCGTACCTT-
CAAGAGAGGTACGGCAGGGTCTTGTTTTTTTA39
pCA-Akt plasmid was kindly provided by Prof. G. Condorelli.
The MDM21–441 and MDM2D150–230 expression plasmids were
previously described [19].
Plasmids MDM2S166A and MDM2S166A/S186A mutant were
generated by Quick Change Site Direct Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) and amplified using the following
primers:
S166A (F) 59GGAGAGCAATTGCTGAGACAGAAG 39,
S166A (R) 59CTTCTGTCTCAGCAATTGCTCTCC 39
S166A/S186A (F) 59 CGCCACAAAGCTGATAGTATTTCC-
C 39
S166A/S186A (R) 59GGGAAATACTATCAGCTTTGTGG-
CG39
PCR was performed with a 2720 Thermo Cycler Applied
Biosystem.
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